6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
discussed	VBN	discussed	discussed	discuss	N	O
in	IN	in	in	in	N	O
greater	JJR	greater	greater	greater	N	O
detail	NN	detail	detail	detail	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
sections	NNS	sections	section	section	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
labeling	NN	labeling	labeling	label	N	O
:	:	:	:	:	N	O

Cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
Toxicities	NNPS	toxicities	toxicity	toxic	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Acute	NNP	acute	acute	acut	N	B-AdverseReaction
Renal	NNP	renal	renal	renal	N	I-AdverseReaction
Failure	NNP	failure	failure	failur	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Tumor	NNP	tumor	tumor	tumor	N	B-AdverseReaction
Lysis	NNP	lysis	lysis	lysi	N	I-AdverseReaction
Syndrome	NNP	syndrome	syndrome	syndrom	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
Toxicity	NNP	toxicity	toxicity	toxic	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
Hypertension	NNP	hypertension	hypertension	hypertens	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Dyspnea	NNP	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Hypertension	NNP	hypertension	hypertension	hypertens	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)]	NN	)]	)]	)]	N	O

Venous	JJ	venous	venous	venou	N	B-AdverseReaction
Thrombosis	NNP	thrombosis	thrombosis	thrombosi	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.8	CD	5.8	5.8	5.8	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Infusion	NN	infusion	infusion	infus	Y	B-AdverseReaction
Reactions	NNP	reactions	reaction	reaction	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.9	CD	5.9	5.9	5.9	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Thrombocytopenia	NNP	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.10	CD	5.10	5.10	5.10	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Hepatic	JJ	hepatic	hepatic	hepat	N	B-AdverseReaction
Toxicity	NNP	toxicity	toxicity	toxic	N	I-AdverseReaction
and	CC	and	and	and	N	O
Hepatic	NNP	hepatic	hepatic	hepat	N	B-AdverseReaction
Failure	NNP	failure	failure	failur	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.11	CD	5.11	5.11	5.11	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Thrombotic	JJ	thrombotic	thrombotic	thrombot	N	B-AdverseReaction
Thrombocytopenic	NNP	thrombocytopenic	thrombocytopenic	thrombocytopen	N	I-AdverseReaction
Purpura	NNP	purpura	purpura	purpura	Y	I-AdverseReaction
Hemolytic	NNP	hemolytic	hemolytic	hemolyt	N	B-AdverseReaction
Uremic	NNP	uremic	uremic	urem	N	I-AdverseReaction
Syndrome	NNP	syndrome	syndrome	syndrom	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.12	CD	5.12	5.12	5.12	N	O
)]	NN	)]	)]	)]	N	O

Posterior	NNP	posterior	posterior	posterior	N	B-AdverseReaction
Reversible	NNP	reversible	reversible	revers	N	I-AdverseReaction
Encephalopathy	NNP	encephalopathy	encephalopathy	encephalopathi	Y	I-AdverseReaction
Syndrome	NNP	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
PRES	NNP	pres	pres	pre	N	B-AdverseReaction
)	)	)	)	)	N	O
[	VBD	[	[	[	N	O
see	JJ	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.13	CD	5.13	5.13	5.13	N	O
)]	NN	)]	)]	)]	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
20%	CD	20%	20%	20%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
in	IN	in	in	in	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
trials	NNS	trials	trial	trial	N	O
:	:	:	:	:	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
platelets	NNS	platelets	platelet	platelet	N	I-AdverseReaction
,	,	,	,	,	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
decreased	VBD	decreased	decreased	decreas	N	B-AdverseReaction
lymphocyte	NN	lymphocyte	lymphocyte	lymphocyt	N	I-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
decreased	VBD	decreased	decreased	decreas	N	B-AdverseReaction
hemoglobin	NN	hemoglobin	hemoglobin	hemoglobin	Y	I-AdverseReaction
,	,	,	,	,	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
,	,	,	,	,	N	O
edema	JJ	edema	edema	edema	Y	B-AdverseReaction
peripheral	NN	peripheral	peripheral	peripher	N	I-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O

The	DT	the	the	the	N	O

most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
20%	CD	20%	20%	20%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
combination	NN	combination	combination	combin	N	O
therapy	NN	therapy	therapy	therapi	N	O
trial	NN	trial	trial	trial	N	O
:	:	:	:	:	N	O
decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
lymphocytes	NNS	lymphocytes	lymphocyte	lymphocyt	Y	I-AdverseReaction
,	,	,	,	,	N	O
decreased	VBD	decreased	decreased	decreas	N	B-AdverseReaction
absolute	JJ	absolute	absolute	absolut	N	I-AdverseReaction
neutrophil	NN	neutrophil	neutrophil	neutrophil	N	I-AdverseReaction
count	NN	count	count	count	N	I-AdverseReaction
,	,	,	,	,	N	O
decreased	VBD	decreased	decreased	decreas	N	B-AdverseReaction
phosphorus	NN	phosphorus	phosphorus	phosphoru	Y	I-AdverseReaction
,	,	,	,	,	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
decreased	VBD	decreased	decreased	decreas	N	B-AdverseReaction
total	JJ	total	total	total	N	I-AdverseReaction
white	JJ	white	white	white	N	I-AdverseReaction
blood	NN	blood	blood	blood	N	I-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
count	NN	count	count	count	N	I-AdverseReaction
,	,	,	,	,	N	O
decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
platelets	NNS	platelets	platelet	platelet	N	I-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
muscle	NN	muscle	muscle	muscl	N	B-AdverseReaction
spasm	NN	spasm	spasm	spasm	N	I-AdverseReaction
,	,	,	,	,	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
,	,	,	,	,	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
decreased	VBD	decreased	decreased	decreas	N	B-AdverseReaction
hemoglobin	NN	hemoglobin	hemoglobin	hemoglobin	Y	I-AdverseReaction
,	,	,	,	,	N	O
hypokalemia	NN	hypokalemia	hypokalemia	hypokalemia	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O
report	VB	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Amgen	NNP	amgen	amgen	amgen	N	O
Medical	NNP	medical	medical	medic	N	O
Information	NNP	information	information	inform	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
77	CD	77	77	77	N	O
-	:	-	-	-	N	O
AMGEN	NNP	amgen	amgen	amgen	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
772	CD	772	772	772	N	O
-	:	-	-	-	N	O
6436	CD	6436	6436	6436	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
medical	JJ	medical	medical	medic	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O
.	.	.	.	.	N	O
1	CD	1	1	1	N	O
Safety	NNP	safety	safety	safeti	N	O
Experience	NNP	experience	experience	experi	N	O
with	IN	with	with	with	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
in	IN	in	in	in	N	O
Combination	NNP	combination	combination	combin	N	O
with	IN	with	with	with	N	O
Lenalidomide	NNP	lenalidomide	lenalidomide	lenalidomid	N	O
and	CC	and	and	and	N	O
Dexamethasone	NNP	dexamethasone	dexamethasone	dexamethason	N	O
in	IN	in	in	in	N	O
Patients	NNP	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Multiple	NNP	multiple	multiple	multipl	N	O
Myeloma	NNP	myeloma	myeloma	myeloma	Y	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
lenalidomide	NN	lenalidomide	lenalidomide	lenalidomid	N	O
and	CC	and	and	and	N	O
dexamethasone	NN	dexamethasone	dexamethasone	dexamethason	N	O
(	(	(	(	(	N	O
KRd	NNP	krd	krd	krd	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
in	IN	in	in	in	N	O
an	DT	an	an	an	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
randomized	VBN	randomized	randomized	random	N	O
study	NN	study	study	studi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
relapsed	JJ	relapsed	relapsed	relaps	N	O
multiple	JJ	multiple	multiple	multipl	N	O
myeloma	NN	myeloma	myeloma	myeloma	Y	O
.	.	.	.	.	N	O

Details	NNS	details	detail	detail	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
study	NN	study	study	studi	N	O
treatment	NN	treatment	treatment	treatment	N	O
are	VBP	are	are	are	N	O
described	VBN	described	described	describ	N	O
in	IN	in	in	in	N	O
Section	NN	section	section	section	N	O
14.1	CD	14.1	14.1	14.1	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
cycles	NNS	cycles	cycle	cycl	N	O
initiated	VBN	initiated	initiated	initi	N	O
was	VBD	was	wa	wa	N	O
22	CD	22	22	22	N	O
cycles	NNS	cycles	cycle	cycl	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
KRd	NNP	krd	krd	krd	N	O
arm	NN	arm	arm	arm	N	O
and	CC	and	and	and	N	O
14	CD	14	14	14	N	O
cycles	NNS	cycles	cycle	cycl	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
Rd	NNP	rd	rd	rd	N	O
arm	NN	arm	arm	arm	N	O
.	.	.	.	.	N	O

Deaths	NNS	deaths	death	death	N	B-AdverseReaction
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
within	IN	within	within	within	N	O
30	CD	30	30	30	N	O
days	NNS	days	day	day	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
last	JJ	last	last	last	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
any	DT	any	any	ani	N	O
therapy	NN	therapy	therapy	therapi	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
KRd	NNP	krd	krd	krd	N	O
arm	NN	arm	arm	arm	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
27	CD	27	27	27	N	O
392	CD	392	392	392	N	O
(	(	(	(	(	N	O
7%	CD	7%	7%	7%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
27	CD	27	27	27	N	O
389	CD	389	389	389	N	O
(	(	(	(	(	N	O
7%	CD	7%	7%	7%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
died	VBD	died	died	die	N	B-AdverseReaction
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
within	IN	within	within	within	N	O
30	CD	30	30	30	N	O
days	NNS	days	day	day	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
last	JJ	last	last	last	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
any	DT	any	any	ani	N	O
Rd	NNP	rd	rd	rd	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
cause	NN	cause	cause	caus	N	O
of	IN	of	of	of	N	O
deaths	NNS	deaths	death	death	N	B-AdverseReaction
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
two	CD	two	two	two	N	O
arms	NNS	arms	arm	arm	N	O
(	(	(	(	(	N	O
KRd	NNP	krd	krd	krd	N	O
versus	NNP	versus	versus	versu	N	O
Rd	NNP	rd	rd	rd	N	O
)	)	)	)	)	N	O
included	VBD	included	included	includ	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
10	CD	10	10	10	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
versus	NN	versus	versus	versu	N	O
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
infection	NN	infection	infection	infect	Y	B-AdverseReaction
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
versus	NN	versus	versus	versu	N	O
10	CD	10	10	10	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
0	CD	0	0	0	N	O
(	(	(	(	(	N	O
0%	CD	0%	0%	0%	N	O
)	)	)	)	)	N	O
versus	NN	versus	versus	versu	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
versus	NN	versus	versus	versu	N	O
10	CD	10	10	10	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
60%	CD	60%	60%	60%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
KRd	NNP	krd	krd	krd	N	O
arm	NN	arm	arm	arm	N	O
and	CC	and	and	and	N	O
54%	CD	54%	54%	54%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Rd	NNP	rd	rd	rd	N	O
arm	NN	arm	arm	arm	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
KRd	NNP	krd	krd	krd	N	O
arm	NN	arm	arm	arm	N	O
as	IN	as	a	as	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
Rd	NNP	rd	rd	rd	N	O
arm	NN	arm	arm	arm	N	O
were	VBD	were	were	were	N	O
pneumonia	NNS	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
(	(	(	(	(	N	O
14%	CD	14%	14%	14%	N	O
versus	IN	versus	versus	versu	N	O
11%	CD	11%	11%	11%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
respiratory	JJ	respiratory	respiratory	respiratori	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
versus	IN	versus	versus	versu	N	O
1.5%	CD	1.5%	1.5%	1.5%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
versus	IN	versus	versus	versu	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
embolism	NN	embolism	embolism	embol	Y	I-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
versus	IN	versus	versus	versu	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
any	DT	any	any	ani	N	O
adverse	JJ	adverse	adverse	advers	N	O
event	NN	event	event	event	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
26%	CD	26%	26%	26%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
KRd	NNP	krd	krd	krd	N	O
arm	NN	arm	arm	arm	N	O
versus	NN	versus	versus	versu	N	O
25%	CD	25%	25%	25%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Rd	NNP	rd	rd	rd	N	O
arm	NN	arm	arm	arm	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
12%	CD	12%	12%	12%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
events	NNS	events	event	event	N	O
included	VBN	included	included	includ	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
myocardial	JJ	myocardial	myocardial	myocardi	N	B-AdverseReaction
infarction	NN	infarction	infarction	infarct	Y	I-AdverseReaction
(	(	(	(	(	N	O
0.8%	CD	0.8%	0.8%	0.8%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
(	(	(	(	(	N	O
0.8%	CD	0.8%	0.8%	0.8%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Common	JJ	common	common	common	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Events	NNP	events	event	event	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O

The	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
12	CD	12	12	12	N	O
cycles	NNS	cycles	cycle	cycl	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
that	WDT	that	that	that	N	O
occurred	VBD	occurred	occurred	occur	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
10%	CD	10%	10%	10%	N	O
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
KRd	NNP	krd	krd	krd	N	O
arm	NN	arm	arm	arm	N	O
are	VBP	are	are	are	N	O
presented	VBN	presented	presented	present	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
5	CD	5	5	5	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
5	CD	5	5	5	N	O
:	:	:	:	:	N	O
Common	JJ	common	common	common	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Events	NNS	events	event	event	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
KRd	NNP	krd	krd	krd	N	O
Arm	NNP	arm	arm	arm	N	O
)	)	)	)	)	N	O
Occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
Cycles	NNP	cycles	cycle	cycl	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
12	CD	12	12	12	N	O
(	(	(	(	(	N	O
Combination	NNP	combination	combination	combin	N	O
Therapy	NNP	therapy	therapy	therapi	N	O
)	)	)	)	)	N	O

KRd	NNP	krd	krd	krd	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
,	,	,	,	,	N	O
lenalidomide	NN	lenalidomide	lenalidomide	lenalidomid	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
low	JJ	low	low	low	N	O
-	:	-	-	-	N	O
dose	NN	dose	dose	dose	N	O
dexamethasone	NN	dexamethasone	dexamethasone	dexamethason	N	O
;	:	;	;	;	N	O
Rd	NNP	rd	rd	rd	N	O
lenalidomide	NN	lenalidomide	lenalidomide	lenalidomid	N	O
and	CC	and	and	and	N	O
low	JJ	low	low	low	N	O
-	:	-	-	-	N	O
dose	NN	dose	dose	dose	N	O
dexamethasone	NN	dexamethasone	dexamethasone	dexamethason	N	O
a	DT	a	a	a	N	O
Pneumonia	NNP	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
includes	VBZ	includes	includes	includ	N	O
preferred	JJ	preferred	preferred	prefer	N	O
terms	NNS	terms	term	term	N	O
of	IN	of	of	of	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
bronchopneumonia	NN	bronchopneumonia	bronchopneumonia	bronchopneumonia	Y	B-AdverseReaction
b	SYM	b	b	b	N	O
Peripheral	NNP	peripheral	peripheral	peripher	N	B-AdverseReaction
neuropathies	NNS	neuropathies	neuropathy	neuropathi	N	I-AdverseReaction
NEC	NNP	nec	nec	nec	N	I-AdverseReaction
includes	VBZ	includes	includes	includ	N	O
preferred	JJ	preferred	preferred	prefer	N	O
terms	NNS	terms	term	term	N	O
under	IN	under	under	under	N	O
HLT	NNP	hlt	hlt	hlt	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
neuropathies	NNS	neuropathies	neuropathy	neuropathi	N	I-AdverseReaction
NEC	NNP	nec	nec	nec	N	I-AdverseReaction
c	VBD	c	c	c	N	O
Dyspnea	NNP	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
includes	VBZ	includes	includes	includ	N	O
preferred	JJ	preferred	preferred	prefer	N	O
terms	NNS	terms	term	term	N	O
of	IN	of	of	of	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
dyspnea	VBP	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
exertional	JJ	exertional	exertional	exert	N	I-AdverseReaction
d	NN	d	d	d	N	O
Embolic	NNP	embolic	embolic	embol	N	B-AdverseReaction
and	CC	and	and	and	N	I-AdverseReaction
thrombotic	JJ	thrombotic	thrombotic	thrombot	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
,	,	,	,	,	N	I-AdverseReaction
venous	JJ	venous	venous	venou	N	I-AdverseReaction
include	VBP	include	include	includ	N	O
preferred	JJ	preferred	preferred	prefer	N	O
terms	NNS	terms	term	term	N	O
in	IN	in	in	in	N	O
MedDRA	NNP	meddra	meddra	meddra	N	O
SMQ	NNP	smq	smq	smq	N	O
narrow	JJ	narrow	narrow	narrow	N	O
scope	NN	scope	scope	scope	N	O
search	NN	search	search	search	N	O
of	IN	of	of	of	N	O
embolic	JJ	embolic	embolic	embol	N	B-AdverseReaction
and	CC	and	and	and	N	I-AdverseReaction
thrombotic	JJ	thrombotic	thrombotic	thrombot	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
,	,	,	,	,	N	I-AdverseReaction
venous	JJ	venous	venous	venou	N	I-AdverseReaction
.	.	.	.	.	N	O

e	DT	e	e	e	N	O
Hypertension	NNP	hypertension	hypertension	hypertens	Y	B-AdverseReaction
includes	VBZ	includes	includes	includ	N	O
preferred	JJ	preferred	preferred	prefer	N	O
terms	NNS	terms	term	term	N	O
of	IN	of	of	of	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypertensive	JJ	hypertensive	hypertensive	hypertens	Y	B-AdverseReaction
crisis	NN	crisis	crisis	crisi	N	I-AdverseReaction
,	,	,	,	,	N	O
hypertensive	JJ	hypertensive	hypertensive	hypertens	Y	B-AdverseReaction
emergency	NN	emergency	emergency	emerg	N	I-AdverseReaction

System	NN	system	system	system	N	O

Organ	NNP	organ	organ	organ	N	O
Class	NNP	class	class	class	N	O
KRd	NNP	krd	krd	krd	N	O
Arm	NNP	arm	arm	arm	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
392	CD	392	392	392	N	O
)	)	)	)	)	N	O
Rd	NNP	rd	rd	rd	N	O
Arm	NNP	arm	arm	arm	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
389	CD	389	389	389	N	O
)	)	)	)	)	N	O

Preferred	JJ	preferred	preferred	prefer	N	O
Term	NNP	term	term	term	N	O
Any	NNP	any	any	ani	N	O
Grade	NNP	grade	grade	grade	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
Any	NNP	any	any	ani	N	O
Grade	NNP	grade	grade	grade	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O

Blood	NN	blood	blood	blood	N	O
and	CC	and	and	and	N	O
Lymphatic	NNP	lymphatic	lymphatic	lymphat	N	O
System	NNP	system	system	system	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Anemia	$	anemia	anemia	anemia	Y	B-AdverseReaction
138	CD	138	138	138	N	O
(	(	(	(	(	N	O
35%	CD	35%	35%	35%	N	O
)	)	)	)	)	N	O
53	CD	53	53	53	N	O
(	(	(	(	(	N	O
14%	CD	14%	14%	14%	N	O
)	)	)	)	)	N	O
127	CD	127	127	127	N	O
(	(	(	(	(	N	O
33%	CD	33%	33%	33%	N	O
)	)	)	)	)	N	O
47	CD	47	47	47	N	O
(	(	(	(	(	N	O
12%	CD	12%	12%	12%	N	O
)	)	)	)	)	N	O

Neutropenia	NNP	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
124	CD	124	124	124	N	O
(	(	(	(	(	N	O
32%	CD	32%	32%	32%	N	O
)	)	)	)	)	N	O
104	CD	104	104	104	N	O
(	(	(	(	(	N	O
27%	CD	27%	27%	27%	N	O
)	)	)	)	)	N	O
115	CD	115	115	115	N	O
(	(	(	(	(	N	O
30%	CD	30%	30%	30%	N	O
)	)	)	)	)	N	O
89	CD	89	89	89	N	O
(	(	(	(	(	N	O
23%	CD	23%	23%	23%	N	O
)	)	)	)	)	N	O

Thrombocytopenia	NNP	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
100	CD	100	100	100	N	O
(	(	(	(	(	N	O
26%	CD	26%	26%	26%	N	O
)	)	)	)	)	N	O
58	CD	58	58	58	N	O
(	(	(	(	(	N	O
15%	CD	15%	15%	15%	N	O
)	)	)	)	)	N	O
75	CD	75	75	75	N	O
(	(	(	(	(	N	O
19%	CD	19%	19%	19%	N	O
)	)	)	)	)	N	O
39	CD	39	39	39	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
115	CD	115	115	115	N	O
(	(	(	(	(	N	O
29%	CD	29%	29%	29%	N	O
)	)	)	)	)	N	O
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
105	CD	105	105	105	N	O
(	(	(	(	(	N	O
27%	CD	27%	27%	27%	N	O
)	)	)	)	)	N	O
12	CD	12	12	12	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O

Constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
68	CD	68	68	68	N	O
(	(	(	(	(	N	O
17%	CD	17%	17%	17%	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
53	CD	53	53	53	N	O
(	(	(	(	(	N	O
14%	CD	14%	14%	14%	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0%	CD	0%	0%	0%	N	O
)	)	)	)	)	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
60	CD	60	60	60	N	O
(	(	(	(	(	N	O
15%	CD	15%	15%	15%	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0%	CD	0%	0%	0%	N	O
)	)	)	)	)	N	O
39	CD	39	39	39	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

General	NNP	general	general	gener	N	O
Disorders	NNP	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
Site	NNP	site	site	site	N	O
Conditions	NNS	conditions	condition	condit	N	O

Fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
109	CD	109	109	109	N	O
(	(	(	(	(	N	O
28%	CD	28%	28%	28%	N	O
)	)	)	)	)	N	O
21	CD	21	21	21	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
104	CD	104	104	104	N	O
(	(	(	(	(	N	O
27%	CD	27%	27%	27%	N	O
)	)	)	)	)	N	O
20	CD	20	20	20	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O

Pyrexia	$	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
93	CD	93	93	93	N	O
(	(	(	(	(	N	O
24%	CD	24%	24%	24%	N	O
)	)	)	)	)	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
64	CD	64	64	64	N	O
(	(	(	(	(	N	O
17%	CD	17%	17%	17%	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0%	CD	0%	0%	0%	N	O
)	)	)	)	)	N	O

Edema	NNP	edema	edema	edema	Y	B-AdverseReaction
Peripheral	NNP	peripheral	peripheral	peripher	N	I-AdverseReaction
63	CD	63	63	63	N	O
(	(	(	(	(	N	O
16%	CD	16%	16%	16%	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
57	CD	57	57	57	N	O
(	(	(	(	(	N	O
15%	CD	15%	15%	15%	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Asthenia	NNP	asthenia	asthenia	asthenia	Y	B-AdverseReaction
53	CD	53	53	53	N	O
(	(	(	(	(	N	O
14%	CD	14%	14%	14%	N	O
)	)	)	)	)	N	O
11	CD	11	11	11	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
46	CD	46	46	46	N	O
(	(	(	(	(	N	O
12%	CD	12%	12%	12%	N	O
)	)	)	)	)	N	O
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
Infestations	NNS	infestations	infestation	infest	N	O

Upper	NNP	upper	upper	upper	N	B-AdverseReaction
Respiratory	NNP	respiratory	respiratory	respiratori	N	I-AdverseReaction
Tract	NNP	tract	tract	tract	N	I-AdverseReaction
Infection	NNP	infection	infection	infect	Y	I-AdverseReaction
85	CD	85	85	85	N	O
(	(	(	(	(	N	O
22%	CD	22%	22%	22%	N	O
)	)	)	)	)	N	O
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
52	CD	52	52	52	N	O
(	(	(	(	(	N	O
13%	CD	13%	13%	13%	N	O
)	)	)	)	)	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Nasopharyngitis	RB	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
63	CD	63	63	63	N	O
(	(	(	(	(	N	O
16%	CD	16%	16%	16%	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
43	CD	43	43	43	N	O
(	(	(	(	(	N	O
11%	CD	11%	11%	11%	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Bronchitis	NN	bronchitis	bronchitis	bronchiti	Y	B-AdverseReaction
54	CD	54	54	54	N	O
(	(	(	(	(	N	O
14%	CD	14%	14%	14%	N	O
)	)	)	)	)	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
39	CD	39	39	39	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Pneumoniaa	$	pneumoniaa	pneumoniaa	pneumoniaa	N	B-AdverseReaction
54	CD	54	54	54	N	O
(	(	(	(	(	N	O
14%	CD	14%	14%	14%	N	O
)	)	)	)	)	N	O
35	CD	35	35	35	N	O
(	(	(	(	(	N	O
9%	CD	9%	9%	9%	N	O
)	)	)	)	)	N	O
43	CD	43	43	43	N	O
(	(	(	(	(	N	O
11%	CD	11%	11%	11%	N	O
)	)	)	)	)	N	O
27	CD	27	27	27	N	O
(	(	(	(	(	N	O
7%	CD	7%	7%	7%	N	O
)	)	)	)	)	N	O

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
Nutrition	NN	nutrition	nutrition	nutrit	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Hypokalemia	$	hypokalemia	hypokalemia	hypokalemia	Y	B-AdverseReaction
78	CD	78	78	78	N	O
(	(	(	(	(	N	O
20%	CD	20%	20%	20%	N	O
)	)	)	)	)	N	O
22	CD	22	22	22	N	O
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O
35	CD	35	35	35	N	O
(	(	(	(	(	N	O
9%	CD	9%	9%	9%	N	O
)	)	)	)	)	N	O
12	CD	12	12	12	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O

Hypocalcemia	$	hypocalcemia	hypocalcemia	hypocalcemia	Y	B-AdverseReaction
55	CD	55	55	55	N	O
(	(	(	(	(	N	O
14%	CD	14%	14%	14%	N	O
)	)	)	)	)	N	O
10	CD	10	10	10	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
39	CD	39	39	39	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Hyperglycemia	$	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
43	CD	43	43	43	N	O
(	(	(	(	(	N	O
11%	CD	11%	11%	11%	N	O
)	)	)	)	)	N	O
18	CD	18	18	18	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
33	CD	33	33	33	N	O
(	(	(	(	(	N	O
9%	CD	9%	9%	9%	N	O
)	)	)	)	)	N	O
15	CD	15	15	15	N	O
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
Connective	NNP	connective	connective	connect	N	O
Tissue	NNP	tissue	tissue	tissu	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Muscle	NNP	muscle	muscle	muscl	N	B-AdverseReaction
Spasms	NNP	spasms	spasm	spasm	Y	I-AdverseReaction
88	CD	88	88	88	N	O
(	(	(	(	(	N	O
22%	CD	22%	22%	22%	N	O
)	)	)	)	)	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
73	CD	73	73	73	N	O
(	(	(	(	(	N	O
19%	CD	19%	19%	19%	N	O
)	)	)	)	)	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
System	NNP	system	system	system	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
Neuropathies	NNP	neuropathies	neuropathy	neuropathi	N	I-AdverseReaction
NECb	NNP	necb	necb	necb	N	I-AdverseReaction
43	CD	43	43	43	N	O
(	(	(	(	(	N	O
11%	CD	11%	11%	11%	N	O
)	)	)	)	)	N	O
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
37	CD	37	37	37	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Insomnia	NNP	insomnia	insomnia	insomnia	Y	B-AdverseReaction
63	CD	63	63	63	N	O
(	(	(	(	(	N	O
16%	CD	16%	16%	16%	N	O
)	)	)	)	)	N	O
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
50	CD	50	50	50	N	O
(	(	(	(	(	N	O
13%	CD	13%	13%	13%	N	O
)	)	)	)	)	N	O
8	CD	8	8	8	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
Thoracic	NNP	thoracic	thoracic	thorac	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Mediastinal	NNP	mediastinal	mediastinal	mediastin	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Cough	IN	cough	cough	cough	Y	B-AdverseReaction
85	CD	85	85	85	N	O
(	(	(	(	(	N	O
22%	CD	22%	22%	22%	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0%	CD	0%	0%	0%	N	O
)	)	)	)	)	N	O
46	CD	46	46	46	N	O
(	(	(	(	(	N	O
12%	CD	12%	12%	12%	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Dyspneac	NNP	dyspneac	dyspneac	dyspneac	N	B-AdverseReaction
70	CD	70	70	70	N	O
(	(	(	(	(	N	O
18%	CD	18%	18%	18%	N	O
)	)	)	)	)	N	O
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
58	CD	58	58	58	N	O
(	(	(	(	(	N	O
15%	CD	15%	15%	15%	N	O
)	)	)	)	)	N	O
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
Subcutaneous	NNP	subcutaneous	subcutaneous	subcutan	N	O
Tissue	NNP	tissue	tissue	tissu	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
45	CD	45	45	45	N	O
(	(	(	(	(	N	O
12%	CD	12%	12%	12%	N	O
)	)	)	)	)	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
53	CD	53	53	53	N	O
(	(	(	(	(	N	O
14%	CD	14%	14%	14%	N	O
)	)	)	)	)	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Vascular	JJ	vascular	vascular	vascular	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Embolic	NNP	embolic	embolic	embol	N	B-AdverseReaction
and	CC	and	and	and	N	I-AdverseReaction
Thrombotic	NNP	thrombotic	thrombotic	thrombot	N	I-AdverseReaction
Events	NNP	events	event	event	N	I-AdverseReaction
,	,	,	,	,	N	I-AdverseReaction
Venousd	NNP	venousd	venousd	venousd	N	I-AdverseReaction
49	CD	49	49	49	N	O
(	(	(	(	(	N	O
13%	CD	13%	13%	13%	N	O
)	)	)	)	)	N	O
16	CD	16	16	16	N	O
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
22	CD	22	22	22	N	O
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O

Hypertensione	$	hypertensione	hypertensione	hypertension	N	B-AdverseReaction
41	CD	41	41	41	N	O
(	(	(	(	(	N	O
11%	CD	11%	11%	11%	N	O
)	)	)	)	)	N	O
12	CD	12	12	12	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
15	CD	15	15	15	N	O
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

There	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
274	CD	274	274	274	N	O
(	(	(	(	(	N	O
70%	CD	70%	70%	70%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
KRd	NNP	krd	krd	krd	N	O
arm	NN	arm	arm	arm	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
treatment	NN	treatment	treatment	treatment	N	O
beyond	IN	beyond	beyond	beyond	N	O
Cycle	NNP	cycle	cycle	cycl	N	O
12	CD	12	12	12	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
no	DT	no	no	no	N	O
new	JJ	new	new	new	N	O
clinically	RB	clinically	clinically	clinic	N	O
relevant	JJ	relevant	relevant	relev	N	O
AEs	NNP	aes	aes	ae	N	O
that	WDT	that	that	that	N	O
emerged	VBD	emerged	emerged	emerg	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
later	JJ	later	later	later	N	O
treatment	NN	treatment	treatment	treatment	N	O
cycles	NNS	cycles	cycle	cycl	N	O
.	.	.	.	.	N	O

Adverse	NN	adverse	adverse	advers	N	O

Reactions	NNS	reactions	reaction	reaction	N	O
Occurring	VBG	occurring	occurring	occur	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
Frequency	NNP	frequency	frequency	frequenc	N	O
of	IN	of	of	of	N	O
10%	CD	10%	10%	10%	N	O

Blood	NN	blood	blood	blood	N	O
and	CC	and	and	and	N	O
lymphatic	JJ	lymphatic	lymphatic	lymphat	N	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
febrile	NN	febrile	febrile	febril	N	B-AdverseReaction
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	I-AdverseReaction
,	,	,	,	,	N	O
lymphopenia	NN	lymphopenia	lymphopenia	lymphopenia	Y	B-AdverseReaction

Cardiac	JJ	cardiac	cardiac	cardiac	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
arrest	NN	arrest	arrest	arrest	N	I-AdverseReaction
,	,	,	,	,	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
congestive	NN	congestive	congestive	congest	N	I-AdverseReaction
,	,	,	,	,	N	O
myocardial	JJ	myocardial	myocardial	myocardi	N	B-AdverseReaction
infarction	NN	infarction	infarction	infarct	Y	I-AdverseReaction
,	,	,	,	,	N	O
myocardial	JJ	myocardial	myocardial	myocardi	N	B-AdverseReaction
ischemia	NN	ischemia	ischemia	ischemia	Y	I-AdverseReaction

Eye	JJ	eye	eye	eye	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
cataract	NN	cataract	cataract	cataract	Y	B-AdverseReaction
,	,	,	,	,	N	O
vision	NN	vision	vision	vision	N	B-AdverseReaction
blurred	VBD	blurred	blurred	blur	N	I-AdverseReaction

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
upper	JJ	upper	upper	upper	N	I-AdverseReaction
,	,	,	,	,	N	O
dyspepsia	NN	dyspepsia	dyspepsia	dyspepsia	Y	B-AdverseReaction
,	,	,	,	,	N	O
toothache	NN	toothache	toothache	toothach	Y	B-AdverseReaction

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O
:	:	:	:	:	N	O
chills	NNS	chills	chill	chill	Y	B-AdverseReaction
,	,	,	,	,	N	O
infusion	NN	infusion	infusion	infus	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
reaction	NN	reaction	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
multi	SYM	multi	multi	multi	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
organ	JJ	organ	organ	organ	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
pain	NN	pain	pain	pain	Y	B-AdverseReaction

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O
:	:	:	:	:	N	O
influenza	NN	influenza	influenza	influenza	Y	B-AdverseReaction
,	,	,	,	,	N	O
sepsis	NN	sepsis	sepsis	sepsi	Y	B-AdverseReaction
,	,	,	,	,	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
viral	JJ	viral	viral	viral	N	B-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
nutrition	NN	nutrition	nutrition	nutrit	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
dehydration	NN	dehydration	dehydration	dehydr	Y	B-AdverseReaction
,	,	,	,	,	N	O
hyperkalemia	NN	hyperkalemia	hyperkalemia	hyperkalemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hyperuricemia	NN	hyperuricemia	hyperuricemia	hyperuricemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypoalbuminemia	NN	hypoalbuminemia	hypoalbuminemia	hypoalbuminemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hyponatremia	NN	hyponatremia	hyponatremia	hyponatremia	Y	B-AdverseReaction
,	,	,	,	,	N	O
tumor	NN	tumor	tumor	tumor	N	B-AdverseReaction
lysis	NN	lysis	lysis	lysi	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
connective	JJ	connective	connective	connect	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
muscular	JJ	muscular	muscular	muscular	N	B-AdverseReaction
weakness	NN	weakness	weakness	weak	Y	I-AdverseReaction
,	,	,	,	,	N	O
myalgia	NN	myalgia	myalgia	myalgia	Y	B-AdverseReaction

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
hypoesthesia	NN	hypoesthesia	hypoesthesia	hypoesthesia	Y	B-AdverseReaction
,	,	,	,	,	N	O
paresthesia	NN	paresthesia	paresthesia	paresthesia	Y	B-AdverseReaction
,	,	,	,	,	N	O
deafness	NN	deafness	deafness	deaf	Y	B-AdverseReaction

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
anxiety	NN	anxiety	anxiety	anxieti	Y	B-AdverseReaction
,	,	,	,	,	N	O
delirium	NN	delirium	delirium	delirium	Y	B-AdverseReaction

Renal	NNP	renal	renal	renal	N	O
and	CC	and	and	and	N	O
urinary	JJ	urinary	urinary	urinari	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
acute	NN	acute	acute	acut	N	I-AdverseReaction
,	,	,	,	,	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
dysphonia	NN	dysphonia	dysphonia	dysphonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
epistaxis	NN	epistaxis	epistaxis	epistaxi	Y	B-AdverseReaction
,	,	,	,	,	N	O
oropharyngeal	JJ	oropharyngeal	oropharyngeal	oropharyng	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
embolism	NN	embolism	embolism	embol	Y	I-AdverseReaction
,	,	,	,	,	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
erythema	NN	erythema	erythema	erythema	Y	B-AdverseReaction
,	,	,	,	,	N	O
hyperhidrosis	NN	hyperhidrosis	hyperhidrosis	hyperhidrosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction

Vascular	JJ	vascular	vascular	vascular	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
deep	JJ	deep	deep	deep	N	B-AdverseReaction
vein	NN	vein	vein	vein	N	I-AdverseReaction
thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	I-AdverseReaction
,	,	,	,	,	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction

Grade	VB	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
and	CC	and	and	and	N	O
higher	JJR	higher	higher	higher	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
occurred	VBD	occurred	occurred	occur	N	O
during	IN	during	during	dure	N	O
Cycles	NNP	cycles	cycle	cycl	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
12	CD	12	12	12	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
substantial	JJ	substantial	substantial	substanti	N	O
difference	NN	difference	difference	differ	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
between	IN	between	between	between	N	O
the	DT	the	the	the	N	O
two	CD	two	two	two	N	O
arms	NNS	arms	arm	arm	N	O
were	VBD	were	were	were	N	O
neutropenia	RB	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypokalemia	NN	hypokalemia	hypokalemia	hypokalemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
hypophosphatemia	NN	hypophosphatemia	hypophosphatemia	hypophosphatemia	Y	B-AdverseReaction
.	.	.	.	.	N	O

Laboratory	NN	laboratory	laboratory	laboratori	N	O

Abnormalities	NNS	abnormalities	abnormality	abnorm	N	O

Table	JJ	table	table	tabl	N	O
6	CD	6	6	6	N	O
describes	NNS	describes	describes	describ	N	O
Grade	VBD	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
reported	VBN	reported	reported	report	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
10%	CD	10%	10%	10%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
KRd	NNP	krd	krd	krd	N	O
arm	NN	arm	arm	arm	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
combination	NN	combination	combination	combin	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
6	CD	6	6	6	N	O
:	:	:	:	:	N	O
Grade	NN	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
Laboratory	NN	laboratory	laboratory	laboratori	N	O
Abnormalities	NNP	abnormalities	abnormality	abnorm	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
Cycles	NNP	cycles	cycle	cycl	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
12	CD	12	12	12	N	O
(	(	(	(	(	N	O
Combination	NNP	combination	combination	combin	N	O
Therapy	NNP	therapy	therapy	therapi	N	O
)	)	)	)	)	N	O

KRd	NNP	krd	krd	krd	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
,	,	,	,	,	N	O
lenalidomide	NN	lenalidomide	lenalidomide	lenalidomid	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
low	JJ	low	low	low	N	O
-	:	-	-	-	N	O
dose	NN	dose	dose	dose	N	O
dexamethasone	NN	dexamethasone	dexamethasone	dexamethason	N	O
;	:	;	;	;	N	O
Rd	NNP	rd	rd	rd	N	O
lenalidomide	NN	lenalidomide	lenalidomide	lenalidomid	N	O
and	CC	and	and	and	N	O
low	JJ	low	low	low	N	O
-	:	-	-	-	N	O
dose	NN	dose	dose	dose	N	O
dexamethasone	NN	dexamethasone	dexamethasone	dexamethason	N	O

Laboratory	NN	laboratory	laboratory	laboratori	N	O

Abnormality	NNP	abnormality	abnormality	abnorm	N	O
KRd	NNP	krd	krd	krd	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
392	CD	392	392	392	N	O
)	)	)	)	)	N	O
Rd	NNP	rd	rd	rd	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
389	CD	389	389	389	N	O
)	)	)	)	)	N	O

Decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
Lymphocytes	VBZ	lymphocytes	lymphocyte	lymphocyt	Y	I-AdverseReaction
182	CD	182	182	182	N	O
(	(	(	(	(	N	O
46%	CD	46%	46%	46%	N	O
)	)	)	)	)	N	O
119	CD	119	119	119	N	O
(	(	(	(	(	N	O
31%	CD	31%	31%	31%	N	O
)	)	)	)	)	N	O

Decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
Absolute	NNP	absolute	absolute	absolut	N	I-AdverseReaction
Neutrophil	NNP	neutrophil	neutrophil	neutrophil	N	I-AdverseReaction
Count	NNP	count	count	count	N	I-AdverseReaction
152	CD	152	152	152	N	O
(	(	(	(	(	N	O
39%	CD	39%	39%	39%	N	O
)	)	)	)	)	N	O
140	CD	140	140	140	N	O
(	(	(	(	(	N	O
36%	CD	36%	36%	36%	N	O
)	)	)	)	)	N	O

Decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
Phosphorus	NNP	phosphorus	phosphorus	phosphoru	Y	I-AdverseReaction
122	CD	122	122	122	N	O
(	(	(	(	(	N	O
31%	CD	31%	31%	31%	N	O
)	)	)	)	)	N	O
106	CD	106	106	106	N	O
(	(	(	(	(	N	O
27%	CD	27%	27%	27%	N	O
)	)	)	)	)	N	O

Decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
Platelets	NNS	platelets	platelet	platelet	N	I-AdverseReaction
101	CD	101	101	101	N	O
(	(	(	(	(	N	O
26%	CD	26%	26%	26%	N	O
)	)	)	)	)	N	O
59	CD	59	59	59	N	O
(	(	(	(	(	N	O
15%	CD	15%	15%	15%	N	O
)	)	)	)	)	N	O

Decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
Total	JJ	total	total	total	N	I-AdverseReaction
White	NNP	white	white	white	N	I-AdverseReaction
Blood	NNP	blood	blood	blood	N	I-AdverseReaction
Cell	NNP	cell	cell	cell	N	I-AdverseReaction
Count	NNP	count	count	count	N	I-AdverseReaction
97	CD	97	97	97	N	O
(	(	(	(	(	N	O
25%	CD	25%	25%	25%	N	O
)	)	)	)	)	N	O
71	CD	71	71	71	N	O
(	(	(	(	(	N	O
18%	CD	18%	18%	18%	N	O
)	)	)	)	)	N	O

Decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
Hemoglobin	$	hemoglobin	hemoglobin	hemoglobin	Y	I-AdverseReaction
58	CD	58	58	58	N	O
(	(	(	(	(	N	O
15%	CD	15%	15%	15%	N	O
)	)	)	)	)	N	O
68	CD	68	68	68	N	O
(	(	(	(	(	N	O
18%	CD	18%	18%	18%	N	O
)	)	)	)	)	N	O

Decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
Potassium	NN	potassium	potassium	potassium	Y	I-AdverseReaction
41	CD	41	41	41	N	O
(	(	(	(	(	N	O
11%	CD	11%	11%	11%	N	O
)	)	)	)	)	N	O
23	CD	23	23	23	N	O
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O

6.1	CD	6.1	6.1	6.1	N	O
.	.	.	.	.	N	O
2	CD	2	2	2	N	O
Safety	NNP	safety	safety	safeti	N	O
Experience	NNP	experience	experience	experi	N	O
with	IN	with	with	with	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
in	IN	in	in	in	N	O
Patients	NNP	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Multiple	NNP	multiple	multiple	multipl	N	O
Myeloma	NNP	myeloma	myeloma	myeloma	Y	O
who	WP	who	who	who	N	O
Received	VBD	received	received	receiv	N	O
Monotherapy	NNP	monotherapy	monotherapy	monotherapi	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
was	VBD	was	wa	wa	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
which	WDT	which	which	which	N	O
598	CD	598	598	598	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
relapsed	JJ	relapsed	relapsed	relaps	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
refractory	JJ	refractory	refractory	refractori	N	O
myeloma	NN	myeloma	myeloma	myeloma	Y	O
received	VBD	received	received	receiv	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
starting	VBG	starting	starting	start	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
20	CD	20	20	20	N	O
mg	NN	mg	mg	mg	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
dose	NN	dose	dose	dose	N	O
in	IN	in	in	in	N	O
Cycle	NNP	cycle	cycle	cycl	N	O
1	CD	1	1	1	N	O
Day	NNP	day	day	day	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
escalating	VBG	escalating	escalating	escal	N	O
to	TO	to	to	to	N	O
27	CD	27	27	27	N	O
mg	NNS	mg	mg	mg	N	O
m	RB	m	m	m	N	O
2	CD	2	2	2	N	O
on	IN	on	on	on	N	O
Cycle	NNP	cycle	cycle	cycl	N	O
1	CD	1	1	1	N	O
Day	NNP	day	day	day	N	O
8	CD	8	8	8	N	O
or	CC	or	or	or	N	O
Cycle	NNP	cycle	cycle	cycl	N	O
2	CD	2	2	2	N	O
Day	NNP	day	day	day	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
was	VBD	was	wa	wa	N	O
64	CD	64	64	64	N	O
years	NNS	years	year	year	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
32	CD	32	32	32	N	O
-	:	-	-	-	N	O
87	CD	87	87	87	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
received	VBD	received	received	receiv	N	O
a	DT	a	a	a	N	O
median	NN	median	median	median	N	O
of	IN	of	of	of	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
20	CD	20	20	20	N	O
)	)	)	)	)	N	O
prior	RB	prior	prior	prior	N	O
regimens	NNS	regimens	regimen	regimen	N	O
.	.	.	.	.	N	O

Approximately	RB	approximately	approximately	approxim	N	O
57%	CD	57%	57%	57%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
male	JJ	male	male	male	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
cycles	NNS	cycles	cycle	cycl	N	O
initiated	VBN	initiated	initiated	initi	N	O
was	VBD	was	wa	wa	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
35	CD	35	35	35	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
,	,	,	,	,	N	O
regardless	RB	regardless	regardless	regardless	N	O
of	IN	of	of	of	N	O
causality	NN	causality	causality	causal	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
50%	CD	50%	50%	50%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
pooled	JJ	pooled	pooled	pool	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
studies	NNS	studies	study	studi	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
598	CD	598	598	598	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
were	VBD	were	were	were	N	O
:	:	:	:	:	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
(	(	(	(	(	N	O
8%	CD	8%	8%	8%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
disease	JJ	disease	disease	diseas	N	B-AdverseReaction
progression	NN	progression	progression	progress	N	I-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
hypercalcemia	NN	hypercalcemia	hypercalcemia	hypercalcemia	Y	B-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
congestive	JJ	congestive	congestive	congest	N	B-AdverseReaction
heart	NN	heart	heart	heart	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
multiple	JJ	multiple	multiple	multipl	N	B-AdverseReaction
myeloma	NN	myeloma	myeloma	myeloma	Y	I-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
was	VBD	was	wa	wa	N	O
higher	RBR	higher	higher	higher	N	O
in	IN	in	in	in	N	O
those	DT	those	those	those	N	O
65	CD	65	65	65	N	O
years	NNS	years	year	year	N	O
old	JJ	old	old	old	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
those	DT	those	those	those	N	O
75	CD	75	75	75	N	O
years	NNS	years	year	year	N	O
old	JJ	old	old	old	N	O
[	JJ	[	[	[	N	O
see	NN	see	see	see	N	O
Geriatric	NNP	geriatric	geriatric	geriatr	N	O
Use	NNP	use	use	use	N	O
(	(	(	(	(	N	O
8.5	CD	8.5	8.5	8.5	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Deaths	NNS	deaths	death	death	N	B-AdverseReaction
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
within	IN	within	within	within	N	O
30	CD	30	30	30	N	O
days	NNS	days	day	day	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
last	JJ	last	last	last	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
30	CD	30	30	30	N	O
598	CD	598	598	598	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
were	VBD	were	were	were	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
disorders	NNS	disorders	disorder	disord	N	I-AdverseReaction
in	IN	in	in	in	N	O
10	CD	10	10	10	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
in	IN	in	in	in	N	O
8	CD	8	8	8	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
disorders	NNS	disorders	disorder	disord	N	I-AdverseReaction
in	IN	in	in	in	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
in	IN	in	in	in	N	O
8	CD	8	8	8	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
randomized	JJ	randomized	randomized	random	N	O
trial	NN	trial	trial	trial	N	O
comparing	VBG	comparing	comparing	compar	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
versus	NN	versus	versus	versu	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
with	IN	with	with	with	N	O
optional	JJ	optional	optional	option	N	O
oral	JJ	oral	oral	oral	N	O
cyclophosphamide	NN	cyclophosphamide	cyclophosphamide	cyclophosphamid	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
relapsed	JJ	relapsed	relapsed	relaps	N	O
and	CC	and	and	and	N	O
refractory	JJ	refractory	refractory	refractori	N	O
multiple	JJ	multiple	multiple	multipl	N	O
myeloma	NN	myeloma	myeloma	myeloma	Y	O
,	,	,	,	,	N	O
mortality	NN	mortality	mortality	mortal	N	B-AdverseReaction
was	VBD	was	wa	wa	N	O
higher	RBR	higher	higher	higher	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
in	IN	in	in	in	N	O
comparison	NN	comparison	comparison	comparison	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
control	NN	control	control	control	N	O
arm	NN	arm	arm	arm	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
subgroup	NN	subgroup	subgroup	subgroup	N	O
of	IN	of	of	of	N	O
48	CD	48	48	48	N	O
patients	NNS	patients	patient	patient	N	O
75	CD	75	75	75	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
cause	NN	cause	cause	caus	N	O
of	IN	of	of	of	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
an	DT	an	an	an	N	O
adverse	JJ	adverse	adverse	advers	N	O
event	NN	event	event	event	N	O
was	VBD	was	wa	wa	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
occurring	VBG	occurring	occurring	occur	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
10%	CD	10%	10%	10%	N	O
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
with	IN	with	with	with	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
are	VBP	are	are	are	N	O
presented	VBN	presented	presented	present	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
7	CD	7	7	7	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
7	CD	7	7	7	N	O
:	:	:	:	:	N	O
Most	JJS	most	most	most	N	O
Commonly	RB	commonly	commonly	commonli	N	O
Reported	VBD	reported	reported	report	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Events	NNS	events	event	event	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
with	IN	with	with	with	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
Monotherapy	NNP	monotherapy	monotherapy	monotherapi	N	O

a	DT	a	a	a	N	O
Pneumonia	NNP	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
includes	VBZ	includes	includes	includ	N	O
the	DT	the	the	the	N	O
preferred	JJ	preferred	preferred	prefer	N	O
terms	NNS	terms	term	term	N	O
of	IN	of	of	of	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
bronchopneumonia	NN	bronchopneumonia	bronchopneumonia	bronchopneumonia	Y	B-AdverseReaction
.	.	.	.	.	N	O

b	SYM	b	b	b	N	O
Peripheral	NNP	peripheral	peripheral	peripher	N	B-AdverseReaction
neuropathies	NNS	neuropathies	neuropathy	neuropathi	N	I-AdverseReaction
NEC	NNP	nec	nec	nec	N	I-AdverseReaction
includes	VBZ	includes	includes	includ	N	O
the	DT	the	the	the	N	O
preferred	JJ	preferred	preferred	prefer	N	O
terms	NNS	terms	term	term	N	O
under	IN	under	under	under	N	O
HLT	NNP	hlt	hlt	hlt	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
neuropathies	NNS	neuropathies	neuropathy	neuropathi	N	I-AdverseReaction
NEC	NNP	nec	nec	nec	N	I-AdverseReaction
.	.	.	.	.	N	O

c	JJ	c	c	c	N	O
Dyspnea	NNP	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
includes	VBZ	includes	includes	includ	N	O
the	DT	the	the	the	N	O
preferred	JJ	preferred	preferred	prefer	N	O
terms	NNS	terms	term	term	N	O
of	IN	of	of	of	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
dyspnea	JJ	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
exertional	NN	exertional	exertional	exert	N	I-AdverseReaction
.	.	.	.	.	N	O

d	JJ	d	d	d	N	O
Hypertension	NNP	hypertension	hypertension	hypertens	Y	B-AdverseReaction
includes	VBZ	includes	includes	includ	N	O
the	DT	the	the	the	N	O
preferred	JJ	preferred	preferred	prefer	N	O
terms	NNS	terms	term	term	N	O
of	IN	of	of	of	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypertensive	JJ	hypertensive	hypertensive	hypertens	Y	B-AdverseReaction
crisis	NN	crisis	crisis	crisi	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
hypertensive	JJ	hypertensive	hypertensive	hypertens	Y	B-AdverseReaction
emergency	NN	emergency	emergency	emerg	N	I-AdverseReaction
.	.	.	.	.	N	O

Kyprolis	NNS	kyprolis	kyprolis	kyproli	N	O

Monotherapy20	NNP	monotherapy20	monotherapy20	monotherapy20	N	O
27	CD	27	27	27	N	O
mg	NN	mg	mg	mg	N	O
m2	NN	m2	m2	m2	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
598	CD	598	598	598	N	O
)	)	)	)	)	N	O

System	NNP	system	system	system	N	O
Organ	NNP	organ	organ	organ	N	O
Class	NNP	class	class	class	N	O
Any	NNP	any	any	ani	N	O
Grade	NNP	grade	grade	grade	N	O
Grade3	NNP	grade3	grade3	grade3	N	O

Blood	NN	blood	blood	blood	N	O
and	CC	and	and	and	N	O
Lymphatic	NNP	lymphatic	lymphatic	lymphat	N	O
System	NNP	system	system	system	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Anemia	$	anemia	anemia	anemia	Y	B-AdverseReaction
291	CD	291	291	291	N	O
(	(	(	(	(	N	O
49%	CD	49%	49%	49%	N	O
)	)	)	)	)	N	O
141	CD	141	141	141	N	O
(	(	(	(	(	N	O
24%	CD	24%	24%	24%	N	O
)	)	)	)	)	N	O

Thrombocytopenia	NNP	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
220	CD	220	220	220	N	O
(	(	(	(	(	N	O
37%	CD	37%	37%	37%	N	O
)	)	)	)	)	N	O
152	CD	152	152	152	N	O
(	(	(	(	(	N	O
25%	CD	25%	25%	25%	N	O
)	)	)	)	)	N	O

Neutropenia	NNP	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
113	CD	113	113	113	N	O
(	(	(	(	(	N	O
19%	CD	19%	19%	19%	N	O
)	)	)	)	)	N	O
63	CD	63	63	63	N	O
(	(	(	(	(	N	O
11%	CD	11%	11%	11%	N	O
)	)	)	)	)	N	O

Lymphopenia	NNP	lymphopenia	lymphopenia	lymphopenia	Y	B-AdverseReaction
85	CD	85	85	85	N	O
(	(	(	(	(	N	O
14%	CD	14%	14%	14%	N	O
)	)	)	)	)	N	O
73	CD	73	73	73	N	O
(	(	(	(	(	N	O
12%	CD	12%	12%	12%	N	O
)	)	)	)	)	N	O

Leukopenia	NNP	leukopenia	leukopenia	leukopenia	Y	B-AdverseReaction
61	CD	61	61	61	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
26	CD	26	26	26	N	O
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
211	CD	211	211	211	N	O
(	(	(	(	(	N	O
35%	CD	35%	35%	35%	N	O
)	)	)	)	)	N	O
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
160	CD	160	160	160	N	O
(	(	(	(	(	N	O
27%	CD	27%	27%	27%	N	O
)	)	)	)	)	N	O
8	CD	8	8	8	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
104	CD	104	104	104	N	O
(	(	(	(	(	N	O
17%	CD	17%	17%	17%	N	O
)	)	)	)	)	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
90	CD	90	90	90	N	O
(	(	(	(	(	N	O
15%	CD	15%	15%	15%	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0%	CD	0%	0%	0%	N	O
)	)	)	)	)	N	O

General	NNP	general	general	gener	N	O
Disorders	NNP	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
Site	NNP	site	site	site	N	O
Conditions	NNS	conditions	condition	condit	N	O

Fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
238	CD	238	238	238	N	O
(	(	(	(	(	N	O
40%	CD	40%	40%	40%	N	O
)	)	)	)	)	N	O
25	CD	25	25	25	N	O
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O

Pyrexia	$	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
177	CD	177	177	177	N	O
(	(	(	(	(	N	O
30%	CD	30%	30%	30%	N	O
)	)	)	)	)	N	O
11	CD	11	11	11	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O

Edema	NNP	edema	edema	edema	Y	B-AdverseReaction
Peripheral	NNP	peripheral	peripheral	peripher	N	I-AdverseReaction
118	CD	118	118	118	N	O
(	(	(	(	(	N	O
20%	CD	20%	20%	20%	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0%	CD	0%	0%	0%	N	O
)	)	)	)	)	N	O

Chills	NNS	chills	chill	chill	Y	B-AdverseReaction
73	CD	73	73	73	N	O
(	(	(	(	(	N	O
12%	CD	12%	12%	12%	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0%	CD	0%	0%	0%	N	O
)	)	)	)	)	N	O

Asthenia	NNP	asthenia	asthenia	asthenia	Y	B-AdverseReaction
71	CD	71	71	71	N	O
(	(	(	(	(	N	O
12%	CD	12%	12%	12%	N	O
)	)	)	)	)	N	O
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
Infestations	NNS	infestations	infestation	infest	N	O

Upper	NNP	upper	upper	upper	N	B-AdverseReaction
Respiratory	NNP	respiratory	respiratory	respiratori	N	I-AdverseReaction
Tract	NNP	tract	tract	tract	N	I-AdverseReaction
Infection	NNP	infection	infection	infect	Y	I-AdverseReaction
112	CD	112	112	112	N	O
(	(	(	(	(	N	O
19%	CD	19%	19%	19%	N	O
)	)	)	)	)	N	O
15	CD	15	15	15	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O

Pneumoniaa	$	pneumoniaa	pneumoniaa	pneumoniaa	N	B-AdverseReaction
71	CD	71	71	71	N	O
(	(	(	(	(	N	O
12%	CD	12%	12%	12%	N	O
)	)	)	)	)	N	O
54	CD	54	54	54	N	O
(	(	(	(	(	N	O
9%	CD	9%	9%	9%	N	O
)	)	)	)	)	N	O

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
Nutrition	NN	nutrition	nutrition	nutrit	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
Appetite	$	appetite	appetite	appetit	N	I-AdverseReaction
89	CD	89	89	89	N	O
(	(	(	(	(	N	O
15%	CD	15%	15%	15%	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
0%	CD	0%	0%	0%	N	O
)	)	)	)	)	N	O

Hypercalcemia	$	hypercalcemia	hypercalcemia	hypercalcemia	Y	B-AdverseReaction
68	CD	68	68	68	N	O
(	(	(	(	(	N	O
11%	CD	11%	11%	11%	N	O
)	)	)	)	)	N	O
26	CD	26	26	26	N	O
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O

Hypokalemia	$	hypokalemia	hypokalemia	hypokalemia	Y	B-AdverseReaction
61	CD	61	61	61	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
17	CD	17	17	17	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
Connective	NNP	connective	connective	connect	N	O
Tissue	NNP	tissue	tissue	tissu	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Back	RB	back	back	back	N	B-AdverseReaction
Pain	NNP	pain	pain	pain	Y	I-AdverseReaction
115	CD	115	115	115	N	O
(	(	(	(	(	N	O
19%	CD	19%	19%	19%	N	O
)	)	)	)	)	N	O
19	CD	19	19	19	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O

Arthralgia	$	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
83	CD	83	83	83	N	O
(	(	(	(	(	N	O
14%	CD	14%	14%	14%	N	O
)	)	)	)	)	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Pain	NN	pain	pain	pain	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
Extremity	NNP	extremity	extremity	extrem	N	I-AdverseReaction
69	CD	69	69	69	N	O
(	(	(	(	(	N	O
12%	CD	12%	12%	12%	N	O
)	)	)	)	)	N	O
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Muscle	NNP	muscle	muscle	muscl	N	B-AdverseReaction
Spasms	NNP	spasms	spasm	spasm	Y	I-AdverseReaction
62	CD	62	62	62	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
0%	CD	0%	0%	0%	N	O
)	)	)	)	)	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	B-AdverseReaction
Pain	NNP	pain	pain	pain	Y	I-AdverseReaction
60	CD	60	60	60	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
12	CD	12	12	12	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
System	NNP	system	system	system	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Headache	$	headache	headache	headach	Y	B-AdverseReaction
141	CD	141	141	141	N	O
(	(	(	(	(	N	O
24%	CD	24%	24%	24%	N	O
)	)	)	)	)	N	O
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
64	CD	64	64	64	N	O
(	(	(	(	(	N	O
11%	CD	11%	11%	11%	N	O
)	)	)	)	)	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
Neuropathies	NNP	neuropathies	neuropathy	neuropathi	N	I-AdverseReaction
NECb	NNP	necb	necb	necb	N	I-AdverseReaction
62	CD	62	62	62	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Insomnia	NNP	insomnia	insomnia	insomnia	Y	B-AdverseReaction
75	CD	75	75	75	N	O
(	(	(	(	(	N	O
13%	CD	13%	13%	13%	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
Thoracic	NNP	thoracic	thoracic	thorac	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Mediastinal	NNP	mediastinal	mediastinal	mediastin	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Dyspneac	NNP	dyspneac	dyspneac	dyspneac	N	B-AdverseReaction
202	CD	202	202	202	N	O
(	(	(	(	(	N	O
34%	CD	34%	34%	34%	N	O
)	)	)	)	)	N	O
21	CD	21	21	21	N	O
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O

Cough	IN	cough	cough	cough	Y	B-AdverseReaction
120	CD	120	120	120	N	O
(	(	(	(	(	N	O
20%	CD	20%	20%	20%	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
0%	CD	0%	0%	0%	N	O
)	)	)	)	)	N	O

Epistaxis	RB	epistaxis	epistaxis	epistaxi	Y	B-AdverseReaction
60	CD	60	60	60	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Renal	JJ	renal	renal	renal	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Renal	JJ	renal	renal	renal	N	B-AdverseReaction
Failure	NN	failure	failure	failur	N	I-AdverseReaction
76	CD	76	76	76	N	O
(	(	(	(	(	N	O
13%	CD	13%	13%	13%	N	O
)	)	)	)	)	N	O
49	CD	49	49	49	N	O
(	(	(	(	(	N	O
8%	CD	8%	8%	8%	N	O
)	)	)	)	)	N	O

Vascular	JJ	vascular	vascular	vascular	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Hypertensiond	$	hypertensiond	hypertensiond	hypertensiond	N	B-AdverseReaction
90	CD	90	90	90	N	O
(	(	(	(	(	N	O
15%	CD	15%	15%	15%	N	O
)	)	)	)	)	N	O
22	CD	22	22	22	N	O
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Occurring	NNP	occurring	occurring	occur	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
Frequency	NNP	frequency	frequency	frequenc	N	O
of	IN	of	of	of	N	O
10%	CD	10%	10%	10%	N	O

Blood	NN	blood	blood	blood	N	O

and	CC	and	and	and	N	O
lymphatic	JJ	lymphatic	lymphatic	lymphat	N	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
febrile	NN	febrile	febrile	febril	N	B-AdverseReaction
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	I-AdverseReaction

Cardiac	JJ	cardiac	cardiac	cardiac	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
arrest	NN	arrest	arrest	arrest	N	I-AdverseReaction
,	,	,	,	,	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
congestive	NN	congestive	congestive	congest	N	I-AdverseReaction
,	,	,	,	,	N	O
myocardial	JJ	myocardial	myocardial	myocardi	N	B-AdverseReaction
infarction	NN	infarction	infarction	infarct	Y	I-AdverseReaction
,	,	,	,	,	N	O
myocardial	JJ	myocardial	myocardial	myocardi	N	B-AdverseReaction
ischemia	NN	ischemia	ischemia	ischemia	Y	I-AdverseReaction

Eye	JJ	eye	eye	eye	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
cataract	NN	cataract	cataract	cataract	Y	B-AdverseReaction
,	,	,	,	,	N	O
blurred	VBN	blurred	blurred	blur	N	B-AdverseReaction
vision	NN	vision	vision	vision	N	I-AdverseReaction

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
upper	JJ	upper	upper	upper	N	I-AdverseReaction
,	,	,	,	,	N	O
dyspepsia	NN	dyspepsia	dyspepsia	dyspepsia	Y	B-AdverseReaction
,	,	,	,	,	N	O
toothache	NN	toothache	toothache	toothach	Y	B-AdverseReaction

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O
:	:	:	:	:	N	O
infusion	NN	infusion	infusion	infus	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
reaction	NN	reaction	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
multi	SYM	multi	multi	multi	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
organ	JJ	organ	organ	organ	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
pain	NN	pain	pain	pain	Y	B-AdverseReaction

Hepatobiliary	JJ	hepatobiliary	hepatobiliary	hepatobiliari	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O
:	:	:	:	:	N	O
bronchitis	NN	bronchitis	bronchitis	bronchiti	Y	B-AdverseReaction
,	,	,	,	,	N	O
influenza	NN	influenza	influenza	influenza	Y	B-AdverseReaction
,	,	,	,	,	N	O
nasopharyngitis	NN	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
,	,	,	,	,	N	O
respiratory	JJ	respiratory	respiratory	respiratori	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
sepsis	NN	sepsis	sepsis	sepsi	Y	B-AdverseReaction
,	,	,	,	,	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
nutrition	NN	nutrition	nutrition	nutrit	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hyperkalemia	NN	hyperkalemia	hyperkalemia	hyperkalemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hyperuricemia	NN	hyperuricemia	hyperuricemia	hyperuricemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypoalbuminemia	NN	hypoalbuminemia	hypoalbuminemia	hypoalbuminemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypocalcemia	NN	hypocalcemia	hypocalcemia	hypocalcemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypomagnesemia	NN	hypomagnesemia	hypomagnesemia	hypomagnesemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hyponatremia	NN	hyponatremia	hyponatremia	hyponatremia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypophosphatemia	NN	hypophosphatemia	hypophosphatemia	hypophosphatemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
tumor	NN	tumor	tumor	tumor	N	B-AdverseReaction
lysis	NN	lysis	lysis	lysi	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
connective	JJ	connective	connective	connect	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
musculoskeletal	JJ	musculoskeletal	musculoskeletal	musculoskelet	N	B-AdverseReaction
chest	NN	chest	chest	chest	N	I-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
myalgia	NN	myalgia	myalgia	myalgia	Y	B-AdverseReaction

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
hypoesthesia	NN	hypoesthesia	hypoesthesia	hypoesthesia	Y	B-AdverseReaction
,	,	,	,	,	N	O
paresthesia	NN	paresthesia	paresthesia	paresthesia	Y	B-AdverseReaction

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
anxiety	NN	anxiety	anxiety	anxieti	Y	B-AdverseReaction

Renal	NNP	renal	renal	renal	N	O
and	CC	and	and	and	N	O
urinary	JJ	urinary	urinary	urinari	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
dysphonia	NN	dysphonia	dysphonia	dysphonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
oropharyngeal	JJ	oropharyngeal	oropharyngeal	oropharyng	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
erythema	NN	erythema	erythema	erythema	Y	B-AdverseReaction
,	,	,	,	,	N	O
hyperhidrosis	NN	hyperhidrosis	hyperhidrosis	hyperhidrosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction

Vascular	JJ	vascular	vascular	vascular	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
embolic	NN	embolic	embolic	embol	N	B-AdverseReaction
and	CC	and	and	and	N	I-AdverseReaction
thrombotic	JJ	thrombotic	thrombotic	thrombot	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
,	,	,	,	,	N	I-AdverseReaction
venous	JJ	venous	venous	venou	N	I-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
deep	JJ	deep	deep	deep	N	B-AdverseReaction
vein	NN	vein	vein	vein	N	I-AdverseReaction
thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	I-AdverseReaction
and	CC	and	and	and	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
embolism	NN	embolism	embolism	embol	Y	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction

Grade	VB	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
and	CC	and	and	and	N	O
higher	JJR	higher	higher	higher	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurring	VBG	occurring	occurring	occur	N	O
at	IN	at	at	at	N	O
an	DT	an	an	an	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
1%	CD	1%	1%	1%	N	O
include	VBP	include	include	includ	N	O
febrile	JJ	febrile	febrile	febril	N	B-AdverseReaction
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	I-AdverseReaction
,	,	,	,	,	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
arrest	NN	arrest	arrest	arrest	N	I-AdverseReaction
,	,	,	,	,	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
congestive	NN	congestive	congestive	congest	N	I-AdverseReaction
,	,	,	,	,	N	O
pain	NN	pain	pain	pain	Y	B-AdverseReaction
,	,	,	,	,	N	O
sepsis	NN	sepsis	sepsis	sepsi	Y	B-AdverseReaction
,	,	,	,	,	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hyperkalemia	NN	hyperkalemia	hyperkalemia	hyperkalemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hyperuricemia	NN	hyperuricemia	hyperuricemia	hyperuricemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypoalbuminemia	NN	hypoalbuminemia	hypoalbuminemia	hypoalbuminemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypocalcemia	NN	hypocalcemia	hypocalcemia	hypocalcemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hyponatremia	NN	hyponatremia	hyponatremia	hyponatremia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypophosphatemia	NN	hypophosphatemia	hypophosphatemia	hypophosphatemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
acute	NN	acute	acute	acut	N	I-AdverseReaction
,	,	,	,	,	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
,	,	,	,	,	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction
.	.	.	.	.	N	O

Laboratory	NN	laboratory	laboratory	laboratori	N	O

Abnormalities	NNS	abnormalities	abnormality	abnorm	N	O

Table	JJ	table	table	tabl	N	O
8	CD	8	8	8	N	O
describes	NNS	describes	describes	describ	N	O
Grade	VBD	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
reported	VBN	reported	reported	report	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
10%	CD	10%	10%	10%	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
8	CD	8	8	8	N	O
:	:	:	:	:	N	O
Grade	NN	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
Laboratory	NN	laboratory	laboratory	laboratori	N	O
Abnormalities	NNP	abnormalities	abnormality	abnorm	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
Monotherapy	NNP	monotherapy	monotherapy	monotherapi	N	O
)	)	)	)	)	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
598	CD	598	598	598	N	O
)	)	)	)	)	N	O

Decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
Platelets	NNS	platelets	platelet	platelet	N	I-AdverseReaction
184	CD	184	184	184	N	O
(	(	(	(	(	N	O
31%	CD	31%	31%	31%	N	O
)	)	)	)	)	N	O

Decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
Lymphocytes	VBZ	lymphocytes	lymphocyte	lymphocyt	Y	I-AdverseReaction
151	CD	151	151	151	N	O
(	(	(	(	(	N	O
25%	CD	25%	25%	25%	N	O
)	)	)	)	)	N	O

Decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
Hemoglobin	$	hemoglobin	hemoglobin	hemoglobin	Y	I-AdverseReaction
132	CD	132	132	132	N	O
(	(	(	(	(	N	O
22%	CD	22%	22%	22%	N	O
)	)	)	)	)	N	O

Decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
Total	JJ	total	total	total	N	I-AdverseReaction
White	NNP	white	white	white	N	I-AdverseReaction
Blood	NNP	blood	blood	blood	N	I-AdverseReaction
Cell	NNP	cell	cell	cell	N	I-AdverseReaction
Count	NNP	count	count	count	N	I-AdverseReaction
71	CD	71	71	71	N	O
(	(	(	(	(	N	O
12%	CD	12%	12%	12%	N	O
)	)	)	)	)	N	O

Decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
Sodium	NN	sodium	sodium	sodium	Y	I-AdverseReaction
69	CD	69	69	69	N	O
(	(	(	(	(	N	O
12%	CD	12%	12%	12%	N	O
)	)	)	)	)	N	O

Decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
Absolute	NNP	absolute	absolute	absolut	N	I-AdverseReaction
Neutrophil	NNP	neutrophil	neutrophil	neutrophil	N	I-AdverseReaction
Count	NNP	count	count	count	N	I-AdverseReaction
67	CD	67	67	67	N	O
(	(	(	(	(	N	O
11%	CD	11%	11%	11%	N	O
)	)	)	)	)	N	O

6.2	CD	6.2	6.2	6.2	N	O
Post	NNP	post	post	post	N	O
-	:	-	-	-	N	O
marketing	NN	marketing	marketing	market	N	O
Experience	NN	experience	experience	experi	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
marketing	NN	marketing	marketing	market	N	O
experience	NN	experience	experience	experi	N	O
with	IN	with	with	with	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
these	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
reported	VBN	reported	reported	report	N	O
voluntarily	RB	voluntarily	voluntarily	voluntarili	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
population	NN	population	population	popul	N	O
of	IN	of	of	of	N	O
uncertain	JJ	uncertain	uncertain	uncertain	N	O
size	NN	size	size	size	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
always	RB	always	always	alway	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
reliably	VB	reliably	reliably	reliabl	N	O
estimate	VB	estimate	estimate	estim	N	O
their	PRP$	their	their	their	N	O
frequency	NN	frequency	frequency	frequenc	N	O
or	CC	or	or	or	N	O
establish	VB	establish	establish	establish	N	O
a	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
to	TO	to	to	to	N	O
drug	NN	drug	drug	drug	N	O
exposure	NN	exposure	exposure	exposur	N	O
:	:	:	:	:	N	O
dehydration	NN	dehydration	dehydration	dehydr	Y	B-AdverseReaction
,	,	,	,	,	N	O
thrombotic	JJ	thrombotic	thrombotic	thrombot	N	B-AdverseReaction
thrombocytopenic	NN	thrombocytopenic	thrombocytopenic	thrombocytopen	N	I-AdverseReaction
purpura	NN	purpura	purpura	purpura	Y	I-AdverseReaction
hemolytic	JJ	hemolytic	hemolytic	hemolyt	N	B-AdverseReaction
uremic	JJ	uremic	uremic	urem	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
TTP	NNP	ttp	ttp	ttp	N	B-AdverseReaction
HUS	NNP	hus	hus	hu	N	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
tumor	JJ	tumor	tumor	tumor	N	B-AdverseReaction
lysis	NN	lysis	lysis	lysi	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
including	VBG	including	including	includ	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
outcomes	NNS	outcomes	outcome	outcom	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
posterior	RB	posterior	posterior	posterior	N	B-AdverseReaction
reversible	JJ	reversible	reversible	revers	N	I-AdverseReaction
encephalopathy	JJ	encephalopathy	encephalopathy	encephalopathi	Y	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
PRES	NNP	pres	pres	pre	N	B-AdverseReaction
)	)	)	)	)	N	O
.	.	.	.	.	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
toxicities	NNS	toxicities	toxicity	toxic	N	I-AdverseReaction
include	VBP	include	include	includ	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
and	CC	and	and	and	N	O
myocardial	JJ	myocardial	myocardial	myocardi	N	B-AdverseReaction
infarction	NN	infarction	infarction	infarct	Y	I-AdverseReaction
with	IN	with	with	with	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
outcome	NN	outcome	outcome	outcom	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
myocardial	JJ	myocardial	myocardial	myocardi	N	B-AdverseReaction
ischemia	NN	ischemia	ischemia	ischemia	Y	I-AdverseReaction
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
and	CC	and	and	and	N	O
evaluate	VB	evaluate	evaluate	evalu	N	O
promptly	RB	promptly	promptly	promptli	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O

Acute	NNP	acute	acute	acut	N	B-AdverseReaction
Renal	NNP	renal	renal	renal	N	I-AdverseReaction
Failure	NN	failure	failure	failur	N	I-AdverseReaction
:	:	:	:	:	N	O
Monitor	NNP	monitor	monitor	monitor	N	O
serum	VBP	serum	serum	serum	N	O
creatinine	NN	creatinine	creatinine	creatinin	Y	O
regularly	RB	regularly	regularly	regularli	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

Tumor	NNP	tumor	tumor	tumor	N	B-AdverseReaction
Lysis	NNP	lysis	lysis	lysi	N	I-AdverseReaction
Syndrome	NNP	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
TLS	NNP	tls	tl	tl	N	B-AdverseReaction
)	)	)	)	)	N	O
:	:	:	:	:	N	O
Administer	NNP	administer	administer	administ	N	O
pre	SYM	pre	pre	pre	N	O
-	:	-	-	-	N	O
treatment	NN	treatment	treatment	treatment	N	O
hydration	NN	hydration	hydration	hydrat	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
2.1	CD	2.1	2.1	2.1	N	O
)	)	)	)	)	N	O
Monitor	NN	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
TLS	NNP	tls	tl	tl	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
uric	JJ	uric	uric	uric	N	O
acid	NN	acid	acid	acid	N	O
levels	NNS	levels	level	level	N	O
and	CC	and	and	and	N	O
treat	NN	treat	treat	treat	N	O
promptly	RB	promptly	promptly	promptli	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

Pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
Toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
:	:	:	:	:	N	O
including	VBG	including	including	includ	N	O
Acute	NNP	acute	acute	acut	N	B-AdverseReaction
Respiratory	NNP	respiratory	respiratory	respiratori	N	I-AdverseReaction
Distress	NNP	distress	distress	distress	N	I-AdverseReaction
Syndrome	NNP	syndrome	syndrome	syndrom	N	I-AdverseReaction
,	,	,	,	,	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
acute	NN	acute	acute	acut	N	B-AdverseReaction
diffuse	NN	diffuse	diffuse	diffus	N	I-AdverseReaction
infiltrative	JJ	infiltrative	infiltrative	infiltr	N	I-AdverseReaction
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
:	:	:	:	:	N	O
Withhold	JJ	withhold	withhold	withhold	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
and	CC	and	and	and	N	O
evaluate	VB	evaluate	evaluate	evalu	N	O
promptly	RB	promptly	promptly	promptli	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

Pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
Hypertension	NN	hypertension	hypertension	hypertens	Y	I-AdverseReaction
:	:	:	:	:	N	O
Withhold	JJ	withhold	withhold	withhold	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
and	CC	and	and	and	N	O
evaluate	VB	evaluate	evaluate	evalu	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O

Dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
:	:	:	:	:	N	O
For	IN	for	for	for	N	O
severe	NN	severe	severe	sever	N	O
or	CC	or	or	or	N	O
life	NN	life	life	life	N	O
threatening	VBG	threatening	threatening	threaten	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	O
,	,	,	,	,	N	O
withhold	JJ	withhold	withhold	withhold	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
and	CC	and	and	and	N	O
evaluate	NN	evaluate	evaluate	evalu	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O

Hypertension	NNP	hypertension	hypertension	hypertens	Y	B-AdverseReaction
including	VBG	including	including	includ	N	O
hypertensive	JJ	hypertensive	hypertensive	hypertens	Y	B-AdverseReaction
crisis	NN	crisis	crisis	crisi	N	I-AdverseReaction
:	:	:	:	:	N	O
Monitor	NNP	monitor	monitor	monitor	N	O
blood	NN	blood	blood	blood	N	O
pressure	NN	pressure	pressure	pressur	N	O
regularly	RB	regularly	regularly	regularli	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
adequately	RB	adequately	adequately	adequ	N	O
controlled	VBN	controlled	controlled	control	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
risk	NN	risk	risk	risk	N	O
-	:	-	-	-	N	O
benefit	NN	benefit	benefit	benefit	N	O
decision	NN	decision	decision	decis	N	O
on	IN	on	on	on	N	O
continued	JJ	continued	continued	continu	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
therapy	NN	therapy	therapy	therapi	N	O
is	VBZ	is	is	is	N	O
needed	VBN	needed	needed	need	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)	)	)	)	)	N	O

Venous	JJ	venous	venous	venou	N	B-AdverseReaction
Thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	I-AdverseReaction
:	:	:	:	:	N	O
Thromboprophylaxis	NN	thromboprophylaxis	thromboprophylaxis	thromboprophylaxi	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.8	CD	5.8	5.8	5.8	N	O
)	)	)	)	)	N	O

Infusion	NN	infusion	infusion	infus	Y	B-AdverseReaction
Reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
:	:	:	:	:	N	O
Pre	NNP	pre	pre	pre	N	O
-	:	-	-	-	N	O
medicate	NN	medicate	medicate	medic	N	O
with	IN	with	with	with	N	O
dexamethasone	NN	dexamethasone	dexamethasone	dexamethason	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
2.1	CD	2.1	2.1	2.1	N	O
,	,	,	,	,	N	O
5.9	CD	5.9	5.9	5.9	N	O
)	)	)	)	)	N	O

Thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
:	:	:	:	:	N	O
Monitor	NNP	monitor	monitor	monitor	N	O
platelet	NN	platelet	platelet	platelet	N	O
counts	NNS	counts	count	count	N	O
;	:	;	;	;	N	O
interrupt	VB	interrupt	interrupt	interrupt	N	O
or	CC	or	or	or	N	O
reduce	VB	reduce	reduce	reduc	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
dosing	VBG	dosing	dosing	dose	N	O
as	IN	as	a	as	N	O
clinically	RB	clinically	clinically	clinic	N	O
indicated	VBN	indicated	indicated	indic	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
2.4	CD	2.4	2.4	2.4	N	O
,	,	,	,	,	N	O
5.10	CD	5.10	5.10	5.10	N	O
)	)	)	)	)	N	O

Hepatic	JJ	hepatic	hepatic	hepat	N	B-AdverseReaction
Toxicity	NNP	toxicity	toxicity	toxic	N	I-AdverseReaction
and	CC	and	and	and	N	O
Hepatic	JJ	hepatic	hepatic	hepat	N	B-AdverseReaction
Failure	NN	failure	failure	failur	N	I-AdverseReaction
:	:	:	:	:	N	O
Monitor	NN	monitor	monitor	monitor	N	O
liver	NN	liver	liver	liver	N	O
enzymes	NNS	enzymes	enzyme	enzym	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
if	IN	if	if	if	N	O
suspected	VBN	suspected	suspected	suspect	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.11	CD	5.11	5.11	5.11	N	O
)	)	)	)	)	N	O

Thrombotic	JJ	thrombotic	thrombotic	thrombot	N	B-AdverseReaction
thrombocytopenic	NN	thrombocytopenic	thrombocytopenic	thrombocytopen	N	I-AdverseReaction
purpura	NN	purpura	purpura	purpura	Y	I-AdverseReaction
hemolytic	JJ	hemolytic	hemolytic	hemolyt	N	B-AdverseReaction
uremic	JJ	uremic	uremic	urem	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
TTP	NNP	ttp	ttp	ttp	N	B-AdverseReaction
HUS	NNP	hus	hus	hu	N	B-AdverseReaction
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
TTP	NNP	ttp	ttp	ttp	N	O
HUS	NNP	hus	hus	hu	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
if	IN	if	if	if	N	O
suspected	VBN	suspected	suspected	suspect	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.12	CD	5.12	5.12	5.12	N	O
)	)	)	)	)	N	O

Posterior	NNP	posterior	posterior	posterior	N	B-AdverseReaction
reversible	JJ	reversible	reversible	revers	N	I-AdverseReaction
encephalopathy	JJ	encephalopathy	encephalopathy	encephalopathi	Y	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
PRES	NNP	pres	pres	pre	N	B-AdverseReaction
)	)	)	)	)	N	O
:	:	:	:	:	N	O
Consider	VB	consider	consider	consid	N	O
neuro	SYM	neuro	neuro	neuro	N	O
-	:	-	-	-	N	O
radiological	JJ	radiological	radiological	radiolog	N	O
imaging	NN	imaging	imaging	imag	N	O
(	(	(	(	(	N	O
MRI	NNP	mri	mri	mri	Y	O
)	)	)	)	)	N	O
for	IN	for	for	for	N	O
onset	NN	onset	onset	onset	N	O
of	IN	of	of	of	N	O
visual	JJ	visual	visual	visual	N	O
or	CC	or	or	or	N	O
neurological	JJ	neurological	neurological	neurolog	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
;	:	;	;	;	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
if	IN	if	if	if	N	O
suspected	VBN	suspected	suspected	suspect	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.13	CD	5.13	5.13	5.13	N	O
)	)	)	)	)	N	O

Embryo	NNP	embryo	embryo	embryo	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
fetal	JJ	fetal	fetal	fetal	N	I-AdverseReaction
Toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
:	:	:	:	:	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
fetal	JJ	fetal	fetal	fetal	N	B-AdverseReaction
harm	NN	harm	harm	harm	N	I-AdverseReaction
.	.	.	.	.	N	O

Females	NNS	females	female	femal	N	O
of	IN	of	of	of	N	O
reproductive	JJ	reproductive	reproductive	reproduct	N	O
potential	NN	potential	potential	potenti	N	O
should	MD	should	should	should	N	O
avoid	VB	avoid	avoid	avoid	N	O
becoming	VBG	becoming	becoming	becom	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
while	IN	while	while	while	N	O
being	VBG	being	being	be	N	O
treated	VBN	treated	treated	treat	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.14	CD	5.14	5.14	5.14	N	O
,	,	,	,	,	N	O
8.1	CD	8.1	8.1	8.1	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Cardiac	NN	cardiac	cardiac	cardiac	N	O

Toxicities	NNS	toxicities	toxicity	toxic	N	O

New	NNP	new	new	new	N	B-AdverseReaction
onset	PRP	onset	onset	onset	N	I-AdverseReaction
or	CC	or	or	or	N	O
worsening	VBG	worsening	worsening	worsen	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
pre	NN	pre	pre	pre	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
existing	VBG	existing	existing	exist	N	I-AdverseReaction
cardiac	JJ	cardiac	cardiac	cardiac	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
congestive	JJ	congestive	congestive	congest	N	B-AdverseReaction
heart	NN	heart	heart	heart	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
,	,	,	,	,	N	O
decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
ejection	NN	ejection	ejection	eject	N	I-AdverseReaction
fraction	NN	fraction	fraction	fraction	N	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
restrictive	JJ	restrictive	restrictive	restrict	N	B-AdverseReaction
cardiomyopathy	NN	cardiomyopathy	cardiomyopathy	cardiomyopathi	Y	I-AdverseReaction
,	,	,	,	,	N	O
myocardial	JJ	myocardial	myocardial	myocardi	N	B-AdverseReaction
ischemia	NN	ischemia	ischemia	ischemia	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
myocardial	JJ	myocardial	myocardial	myocardi	N	B-AdverseReaction
infarction	NN	infarction	infarction	infarct	Y	I-AdverseReaction
including	VBG	including	including	includ	N	O
fatalities	NNS	fatalities	fatality	fatal	N	B-AdverseReaction
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
following	JJ	following	following	follow	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
with	IN	with	with	with	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
,	,	,	,	,	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
typically	RB	typically	typically	typic	N	O
occurred	VBD	occurred	occurred	occur	N	O
early	RB	early	early	earli	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
course	NN	course	course	cours	N	O
of	IN	of	of	of	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
therapy	NN	therapy	therapy	therapi	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
cycles	NNS	cycles	cycle	cycl	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Death	NN	death	death	death	Y	B-AdverseReaction
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
arrest	NN	arrest	arrest	arrest	N	I-AdverseReaction
has	VBZ	has	ha	ha	N	O
occurred	VBN	occurred	occurred	occur	N	O
within	IN	within	within	within	N	O
a	DT	a	a	a	N	O
day	NN	day	day	day	N	O
of	IN	of	of	of	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
administration	NN	administration	administration	administr	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
for	IN	for	for	for	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
or	CC	or	or	or	N	O
4	CD	4	4	4	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
until	IN	until	until	until	N	O
recovery	NN	recovery	recovery	recoveri	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
consider	VB	consider	consider	consid	N	O
whether	IN	whether	whether	whether	N	O
to	TO	to	to	to	N	O
restart	VB	restart	restart	restart	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
dose	JJ	dose	dose	dose	N	O
level	NN	level	level	level	N	O
reduction	NN	reduction	reduction	reduct	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
a	DT	a	a	a	N	O
benefit	NN	benefit	benefit	benefit	N	O
risk	NN	risk	risk	risk	N	O
assessment	NN	assessment	assessment	assess	N	O
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

While	IN	while	while	while	N	O
adequate	JJ	adequate	adequate	adequ	N	O
hydration	NN	hydration	hydration	hydrat	N	O
is	VBZ	is	is	is	N	O
required	VBN	required	required	requir	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
each	DT	each	each	each	N	O
dose	NN	dose	dose	dose	N	O
in	IN	in	in	in	N	O
Cycle	NNP	cycle	cycle	cycl	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
all	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
also	RB	also	also	also	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
for	IN	for	for	for	N	O
evidence	NN	evidence	evidence	evid	N	O
of	IN	of	of	of	N	O
volume	NN	volume	volume	volum	N	O
overload	NN	overload	overload	overload	N	O
,	,	,	,	,	N	O
especially	RB	especially	especially	especi	N	O
patients	NNS	patients	patient	patient	N	O
at	IN	at	at	at	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	O
failure	NN	failure	failure	failur	N	O
.	.	.	.	.	N	O

Adjust	NNP	adjust	adjust	adjust	N	O
total	JJ	total	total	total	N	O
fluid	NN	fluid	fluid	fluid	N	O
intake	NN	intake	intake	intak	N	O
as	IN	as	a	as	N	O
clinically	RB	clinically	clinically	clinic	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
baseline	JJ	baseline	baseline	baselin	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	O
failure	NN	failure	failure	failur	N	O
or	CC	or	or	or	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
at	IN	at	at	at	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	O
failure	NN	failure	failure	failur	N	O
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
75	CD	75	75	75	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	O
failure	NN	failure	failure	failur	N	O
is	VBZ	is	is	is	N	O
increased	VBN	increased	increased	increas	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
New	NNP	new	new	new	N	O
York	NNP	york	york	york	N	O
Heart	NNP	heart	heart	heart	N	O
Association	NNP	association	association	associ	N	O
Class	NNP	class	class	class	N	O
III	NNP	iii	iii	iii	N	O
and	CC	and	and	and	N	O
IV	NNP	iv	iv	iv	N	O
heart	NN	heart	heart	heart	N	O
failure	NN	failure	failure	failur	N	O
,	,	,	,	,	N	O
recent	JJ	recent	recent	recent	N	O
myocardial	JJ	myocardial	myocardial	myocardi	N	O
infarction	NN	infarction	infarction	infarct	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
conduction	NN	conduction	conduction	conduct	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
uncontrolled	VBN	uncontrolled	uncontrolled	uncontrol	N	O
by	IN	by	by	by	N	O
medications	NNS	medications	medication	medic	N	O
were	VBD	were	were	were	N	O
not	RB	not	not	not	N	O
eligible	JJ	eligible	eligible	elig	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
at	IN	at	at	at	N	O
greater	JJR	greater	greater	greater	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	O
complications	NNS	complications	complication	complic	N	O
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8	CD	8	8	8	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Acute	NNP	acute	acute	acut	N	O
Renal	NNP	renal	renal	renal	N	O
Failure	NN	failure	failure	failur	N	O

Cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
.	.	.	.	.	N	O

Renal	JJ	renal	renal	renal	N	B-AdverseReaction
insufficiency	NN	insufficiency	insufficiency	insuffici	N	I-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
(	(	(	(	(	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
,	,	,	,	,	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
)	)	)	)	)	N	O
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
approximately	RB	approximately	approximately	approxim	N	O
8%	CD	8%	8%	8%	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
randomized	NN	randomized	randomized	random	N	O
controlled	VBN	controlled	controlled	control	N	O
trial	NN	trial	trial	trial	N	O
.	.	.	.	.	N	O

Acute	NNP	acute	acute	acut	N	B-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
advanced	JJ	advanced	advanced	advanc	N	O
relapsed	VBN	relapsed	relapsed	relaps	N	O
and	CC	and	and	and	N	O
refractory	JJ	refractory	refractory	refractori	N	O
multiple	JJ	multiple	multiple	multipl	N	O
myeloma	NN	myeloma	myeloma	myeloma	Y	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
.	.	.	.	.	N	O

This	DT	this	this	thi	N	O
risk	NN	risk	risk	risk	N	O
was	VBD	was	wa	wa	N	O
greater	JJR	greater	greater	greater	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
baseline	NN	baseline	baseline	baselin	N	O
reduced	VBN	reduced	reduced	reduc	N	O
estimated	VBN	estimated	estimated	estim	N	O
creatinine	JJ	creatinine	creatinine	creatinin	Y	O
clearance	NN	clearance	clearance	clearanc	N	O
(	(	(	(	(	N	O
calculated	VBN	calculated	calculated	calcul	N	O
using	VBG	using	using	use	N	O
Cockcroft	NNP	cockcroft	cockcroft	cockcroft	N	O
and	CC	and	and	and	N	O
Gault	NNP	gault	gault	gault	N	O
equation	NN	equation	equation	equat	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
with	IN	with	with	with	N	O
regular	JJ	regular	regular	regular	N	O
measurement	NN	measurement	measurement	measur	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
serum	NN	serum	serum	serum	N	O
creatinine	NN	creatinine	creatinine	creatinin	Y	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
estimated	VBN	estimated	estimated	estim	N	O
creatinine	JJ	creatinine	creatinine	creatinin	Y	O
clearance	NN	clearance	clearance	clearanc	N	O
.	.	.	.	.	N	O

Reduce	NNP	reduce	reduce	reduc	N	O
or	CC	or	or	or	N	O
withhold	RB	withhold	withhold	withhold	N	O
dose	JJ	dose	dose	dose	N	O
as	IN	as	a	as	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Tumor	NNP	tumor	tumor	tumor	N	O
Lysis	NNP	lysis	lysis	lysi	N	O
Syndrome	NNP	syndrome	syndrome	syndrom	N	O

Cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
tumor	NN	tumor	tumor	tumor	N	B-AdverseReaction
lysis	NN	lysis	lysis	lysi	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
TLS	NNP	tls	tl	tl	N	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
outcomes	NNS	outcomes	outcome	outcom	N	O
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
multiple	JJ	multiple	multiple	multipl	N	O
myeloma	NN	myeloma	myeloma	myeloma	Y	O
and	CC	and	and	and	N	O
a	DT	a	a	a	N	O
high	JJ	high	high	high	N	O
tumor	NN	tumor	tumor	tumor	N	O
burden	NN	burden	burden	burden	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
at	IN	at	at	at	N	O
greater	JJR	greater	greater	greater	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
TLS	NNP	tls	tl	tl	N	O
.	.	.	.	.	N	O

Ensure	NN	ensure	ensure	ensur	N	O
that	IN	that	that	that	N	O
patients	NNS	patients	patient	patient	N	O
are	VBP	are	are	are	N	O
well	RB	well	well	well	N	O
hydrated	VBN	hydrated	hydrated	hydrat	N	O
before	IN	before	before	befor	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
in	IN	in	in	in	N	O
Cycle	NNP	cycle	cycle	cycl	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
subsequent	JJ	subsequent	subsequent	subsequ	N	O
cycles	NNS	cycles	cycle	cycl	N	O
as	IN	as	a	as	N	O
needed	JJ	needed	needed	need	N	O
[	NN	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
uric	JJ	uric	uric	uric	N	O
acid	NN	acid	acid	acid	N	O
lowering	VBG	lowering	lowering	lower	N	O
drugs	NNS	drugs	drug	drug	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
at	IN	at	at	at	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
TLS	NNP	tls	tl	tl	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
evidence	NN	evidence	evidence	evid	N	O
of	IN	of	of	of	N	O
TLS	NNP	tls	tl	tl	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
and	CC	and	and	and	N	O
manage	NN	manage	manage	manag	N	O
promptly	RB	promptly	promptly	promptli	N	O
including	VBG	including	including	includ	N	O
interruption	NN	interruption	interruption	interrupt	N	O
of	IN	of	of	of	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
until	IN	until	until	until	N	O
TLS	NNP	tls	tl	tl	N	O
is	VBZ	is	is	is	N	O
resolved	VBN	resolved	resolved	resolv	N	O
[	JJ	[	[	[	N	O
see	NN	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	O
Toxicity	NN	toxicity	toxicity	toxic	N	O

Acute	NNP	acute	acute	acut	N	B-AdverseReaction
Respiratory	NNP	respiratory	respiratory	respiratori	N	I-AdverseReaction
Distress	NNP	distress	distress	distress	N	I-AdverseReaction
Syndrome	NNP	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
ARDS	NNP	ards	ards	ard	Y	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
acute	NN	acute	acute	acut	N	B-AdverseReaction
diffuse	NN	diffuse	diffuse	diffus	N	I-AdverseReaction
infiltrative	JJ	infiltrative	infiltrative	infiltr	N	I-AdverseReaction
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
and	CC	and	and	and	N	O
interstitial	JJ	interstitial	interstitial	interstiti	N	B-AdverseReaction
lung	NN	lung	lung	lung	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
.	.	.	.	.	N	O

Some	DT	some	some	some	N	O
events	NNS	events	event	event	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
event	NN	event	event	event	N	O
of	IN	of	of	of	N	O
drug	NN	drug	drug	drug	N	O
-	:	-	-	-	N	O
induced	JJ	induced	induced	induc	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	O
toxicity	NN	toxicity	toxicity	toxic	N	O
,	,	,	,	,	N	O
discontinue	NN	discontinue	discontinue	discontinu	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	O
Hypertension	NN	hypertension	hypertension	hypertens	Y	O

Pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
arterial	JJ	arterial	arterial	arteri	N	I-AdverseReaction
hypertension	NN	hypertension	hypertension	hypertens	Y	I-AdverseReaction
(	(	(	(	(	N	O
PAH	NNP	pah	pah	pah	N	B-AdverseReaction
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
approximately	RB	approximately	approximately	approxim	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
and	CC	and	and	and	N	O
was	VBD	was	wa	wa	N	O
Grade	VBN	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
in	IN	in	in	in	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Evaluate	NN	evaluate	evaluate	evalu	N	O
with	IN	with	with	with	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	O
imaging	NN	imaging	imaging	imag	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
tests	NNS	tests	test	test	N	O
as	IN	as	a	as	N	O
indicated	JJ	indicated	indicated	indic	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
for	IN	for	for	for	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	O
until	IN	until	until	until	N	O
resolved	VBN	resolved	resolved	resolv	N	O
or	CC	or	or	or	N	O
returned	VBN	returned	returned	return	N	O
to	TO	to	to	to	N	O
baseline	VB	baseline	baseline	baselin	N	O
and	CC	and	and	and	N	O
consider	VB	consider	consider	consid	N	O
whether	IN	whether	whether	whether	N	O
to	TO	to	to	to	N	O
restart	VB	restart	restart	restart	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
a	DT	a	a	a	N	O
benefit	NN	benefit	benefit	benefit	N	O
risk	NN	risk	risk	risk	N	O
assessment	NN	assessment	assessment	assess	N	O
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	O

Dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
28%	CD	28%	28%	28%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
and	CC	and	and	and	N	O
was	VBD	was	wa	wa	N	O
Grade	VBN	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
in	IN	in	in	in	N	O
4%	CD	4%	4%	4%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Evaluate	NNP	evaluate	evaluate	evalu	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	O
to	TO	to	to	to	N	O
exclude	VB	exclude	exclude	exclud	N	O
cardiopulmonary	JJ	cardiopulmonary	cardiopulmonary	cardiopulmonari	N	O
conditions	NNS	conditions	condition	condit	N	O
including	VBG	including	including	includ	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	O
failure	NN	failure	failure	failur	N	O
and	CC	and	and	and	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	O
syndromes	NNS	syndromes	syndrome	syndrom	N	O
.	.	.	.	.	N	O

Stop	NNP	stop	stop	stop	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
for	IN	for	for	for	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
or	CC	or	or	or	N	O
4	CD	4	4	4	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	O
until	IN	until	until	until	N	O
resolved	VBD	resolved	resolved	resolv	N	O
or	CC	or	or	or	N	O
returned	VBN	returned	returned	return	N	O
to	TO	to	to	to	N	O
baseline	VB	baseline	baseline	baselin	N	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
whether	IN	whether	whether	whether	N	O
to	TO	to	to	to	N	O
restart	VB	restart	restart	restart	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
a	DT	a	a	a	N	O
benefit	NN	benefit	benefit	benefit	N	O
risk	NN	risk	risk	risk	N	O
assessment	NN	assessment	assessment	assess	N	O
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
-	:	-	-	-	N	O
Cardiac	JJ	cardiac	cardiac	cardiac	N	O
Toxicities	NNP	toxicities	toxicity	toxic	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Pulmonary	NNP	pulmonary	pulmonary	pulmonari	N	O
Toxicity	NNP	toxicity	toxicity	toxic	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O
Hypertension	NN	hypertension	hypertension	hypertens	Y	O

Hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
hypertensive	JJ	hypertensive	hypertensive	hypertens	Y	B-AdverseReaction
crisis	NN	crisis	crisis	crisi	N	I-AdverseReaction
and	CC	and	and	and	N	O
hypertensive	JJ	hypertensive	hypertensive	hypertens	Y	B-AdverseReaction
emergency	NN	emergency	emergency	emerg	N	I-AdverseReaction
,	,	,	,	,	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
with	IN	with	with	with	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
.	.	.	.	.	N	O

Some	DT	some	some	some	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
blood	NN	blood	blood	blood	N	O
pressure	NN	pressure	pressure	pressur	N	O
regularly	RB	regularly	regularly	regularli	N	O
in	IN	in	in	in	N	O
all	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
adequately	RB	adequately	adequately	adequ	N	O
controlled	VBN	controlled	controlled	control	N	O
,	,	,	,	,	N	O
withhold	VB	withhold	withhold	withhold	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
and	CC	and	and	and	N	O
evaluate	NN	evaluate	evaluate	evalu	N	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
whether	IN	whether	whether	whether	N	O
to	TO	to	to	to	N	O
restart	VB	restart	restart	restart	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
a	DT	a	a	a	N	O
benefit	NN	benefit	benefit	benefit	N	O
risk	NN	risk	risk	risk	N	O
assessment	NN	assessment	assessment	assess	N	O
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.8	CD	5.8	5.8	5.8	N	O
Venous	JJ	venous	venous	venou	N	O
Thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	O

Venous	JJ	venous	venous	venou	N	B-AdverseReaction
thromboembolic	JJ	thromboembolic	thromboembolic	thromboembol	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
deep	RB	deep	deep	deep	N	B-AdverseReaction
venous	JJ	venous	venous	venou	N	I-AdverseReaction
thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	I-AdverseReaction
and	CC	and	and	and	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
embolism	NN	embolism	embolism	embol	Y	I-AdverseReaction
)	)	)	)	)	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
with	IN	with	with	with	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
combination	NN	combination	combination	combin	N	O
study	NN	study	study	studi	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
venous	JJ	venous	venous	venou	N	B-AdverseReaction
thromboembolic	JJ	thromboembolic	thromboembolic	thromboembol	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
12	CD	12	12	12	N	O
cycles	NNS	cycles	cycle	cycl	N	O
was	VBD	was	wa	wa	N	O
13%	CD	13%	13%	13%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
combination	NN	combination	combination	combin	N	O
arm	NN	arm	arm	arm	N	O
versus	NN	versus	versus	versu	N	O
6%	CD	6%	6%	6%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
control	NN	control	control	control	N	O
arm	NN	arm	arm	arm	N	O
.	.	.	.	.	N	O

With	IN	with	with	with	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
venous	JJ	venous	venous	venou	N	B-AdverseReaction
thromboembolic	JJ	thromboembolic	thromboembolic	thromboembol	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
2%	CD	2%	2%	2%	N	O
.	.	.	.	.	N	O

Thromboprophylaxis	NNP	thromboprophylaxis	thromboprophylaxis	thromboprophylaxi	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
and	CC	and	and	and	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
an	DT	an	an	an	N	O
assessment	NN	assessment	assessment	assess	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
's	POS	's	's	's	N	O
underlying	JJ	underlying	underlying	underli	N	O
risks	NNS	risks	risk	risk	N	O
,	,	,	,	,	N	O
treatment	NN	treatment	treatment	treatment	N	O
regimen	NNS	regimen	regimen	regimen	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
clinical	JJ	clinical	clinical	clinic	N	O
status	NN	status	status	statu	N	O
.	.	.	.	.	N	O

5.9	CD	5.9	5.9	5.9	N	O
Infusion	NNP	infusion	infusion	infus	Y	O
Reactions	NNS	reactions	reaction	reaction	N	O

Infusion	NN	infusion	infusion	infus	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
life	NN	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	JJ	threatening	threatening	threaten	N	I-Severity
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
.	.	.	.	.	N	O

Symptoms	NNP	symptoms	symptom	symptom	N	O
include	VBP	include	include	includ	N	O
fever	NN	fever	fever	fever	Y	B-AdverseReaction
,	,	,	,	,	N	O
chills	NNS	chills	chill	chill	Y	B-AdverseReaction
,	,	,	,	,	N	O
arthralgia	NN	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
,	,	,	,	,	N	O
myalgia	NN	myalgia	myalgia	myalgia	Y	B-AdverseReaction
,	,	,	,	,	N	O
facial	JJ	facial	facial	facial	N	B-AdverseReaction
flushing	NN	flushing	flushing	flush	Y	I-AdverseReaction
,	,	,	,	,	N	O
facial	JJ	facial	facial	facial	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
weakness	NN	weakness	weakness	weak	Y	B-AdverseReaction
,	,	,	,	,	N	O
shortness	NN	shortness	shortness	short	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
breath	NN	breath	breath	breath	N	I-AdverseReaction
,	,	,	,	,	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction
,	,	,	,	,	N	O
syncope	NN	syncope	syncope	syncop	Y	B-AdverseReaction
,	,	,	,	,	N	O
chest	NN	chest	chest	chest	N	B-AdverseReaction
tightness	NN	tightness	tightness	tight	N	I-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
angina	NN	angina	angina	angina	N	B-AdverseReaction
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
can	MD	can	can	can	N	O
occur	VB	occur	occur	occur	N	O
immediately	RB	immediately	immediately	immedi	N	O
following	VBG	following	following	follow	N	O
or	CC	or	or	or	N	O
up	RB	up	up	up	N	O
to	TO	to	to	to	N	O
24	CD	24	24	24	N	O
hours	NNS	hours	hour	hour	N	O
after	IN	after	after	after	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
.	.	.	.	.	N	O

Administer	NNP	administer	administer	administ	N	O
dexamethasone	NN	dexamethasone	dexamethasone	dexamethason	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
to	TO	to	to	to	N	O
reduce	VB	reduce	reduce	reduc	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
and	CC	and	and	and	N	O
severity	NN	severity	severity	sever	N	O
of	IN	of	of	of	N	O
infusion	NN	infusion	infusion	infus	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Inform	NNP	inform	inform	inform	N	O
patients	NNS	patients	patient	patient	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
and	CC	and	and	and	N	O
of	IN	of	of	of	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
and	CC	and	and	and	N	O
to	TO	to	to	to	N	O
contact	VB	contact	contact	contact	N	O
a	DT	a	a	a	N	O
physician	NN	physician	physician	physician	N	O
immediately	RB	immediately	immediately	immedi	N	O
if	IN	if	if	if	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
an	DT	an	an	an	N	O
infusion	NN	infusion	infusion	infus	Y	O
reaction	NN	reaction	reaction	reaction	N	O
occur	VBP	occur	occur	occur	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Patient	NNP	patient	patient	patient	N	O
Counseling	NNP	counseling	counseling	counsel	N	O
Information	NNP	information	information	inform	N	O
(	(	(	(	(	N	O
17	CD	17	17	17	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.10	CD	5.10	5.10	5.10	N	O
Thrombocytopenia	NNP	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	O

Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
causes	VBZ	causes	cause	caus	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
with	IN	with	with	with	N	O
platelet	NN	platelet	platelet	platelet	N	B-AdverseReaction
nadirs	NNS	nadirs	nadir	nadir	N	I-AdverseReaction
observed	VBD	observed	observed	observ	N	O
between	IN	between	between	between	N	O
Day	NNP	day	day	day	N	O
8	CD	8	8	8	N	O
and	CC	and	and	and	N	O
Day	NNP	day	day	day	N	O
15	CD	15	15	15	N	O
of	IN	of	of	of	N	O
each	DT	each	each	each	N	O
28	CD	28	28	28	N	O
-	:	-	-	-	N	O
day	NN	day	day	day	N	O
cycle	NN	cycle	cycle	cycl	N	O
with	IN	with	with	with	N	O
recovery	NN	recovery	recovery	recoveri	N	O
to	TO	to	to	to	N	O
baseline	VB	baseline	baseline	baselin	N	O
platelet	NN	platelet	platelet	platelet	N	O
count	NN	count	count	count	N	O
usually	RB	usually	usually	usual	N	O
by	IN	by	by	by	N	O
the	DT	the	the	the	N	O
start	NN	start	start	start	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
next	JJ	next	next	next	N	O
cycle	NN	cycle	cycle	cycl	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Thrombocytopenia	NNP	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
approximately	RB	approximately	approximately	approxim	N	O
40%	CD	40%	40%	40%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
with	IN	with	with	with	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
platelet	NN	platelet	platelet	platelet	N	O
counts	VBZ	counts	count	count	N	O
frequently	RB	frequently	frequently	frequent	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
.	.	.	.	.	N	O

Reduce	NNP	reduce	reduce	reduc	N	O
or	CC	or	or	or	N	O
withhold	RB	withhold	withhold	withhold	N	O
dose	JJ	dose	dose	dose	N	O
as	IN	as	a	as	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.11	CD	5.11	5.11	5.11	N	O
Hepatic	JJ	hepatic	hepatic	hepat	N	O
Toxicity	NNP	toxicity	toxicity	toxic	N	O
and	CC	and	and	and	N	O
Hepatic	NNP	hepatic	hepatic	hepat	N	O
Failure	NNP	failure	failure	failur	N	O

Cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
cases	NNS	cases	case	case	N	O
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
.	.	.	.	.	N	O

Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
increased	JJ	increased	increased	increas	N	B-AdverseReaction
serum	NN	serum	serum	serum	N	I-AdverseReaction
transaminases	NNS	transaminases	transaminase	transaminas	Y	I-AdverseReaction
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
liver	NN	liver	liver	liver	N	O
enzymes	VBZ	enzymes	enzyme	enzym	N	O
regularly	RB	regularly	regularly	regularli	N	O
.	.	.	.	.	N	O

Reduce	NNP	reduce	reduce	reduc	N	O
or	CC	or	or	or	N	O
withhold	RB	withhold	withhold	withhold	N	O
dose	JJ	dose	dose	dose	N	O
as	IN	as	a	as	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.12	CD	5.12	5.12	5.12	N	O
Thrombotic	NNP	thrombotic	thrombotic	thrombot	N	O
Thrombocytopenic	NNP	thrombocytopenic	thrombocytopenic	thrombocytopen	N	O
Purpura	NNP	purpura	purpura	purpura	Y	O
Hemolytic	NNP	hemolytic	hemolytic	hemolyt	N	O
Uremic	NNP	uremic	uremic	urem	N	O
Syndrome	NNP	syndrome	syndrome	syndrom	N	O

Cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
thrombotic	JJ	thrombotic	thrombotic	thrombot	N	B-AdverseReaction
thrombocytopenic	JJ	thrombocytopenic	thrombocytopenic	thrombocytopen	N	I-AdverseReaction
purpura	NN	purpura	purpura	purpura	Y	I-AdverseReaction
hemolytic	JJ	hemolytic	hemolytic	hemolyt	N	B-AdverseReaction
uremic	JJ	uremic	uremic	urem	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
TTP	NNP	ttp	ttp	ttp	N	B-AdverseReaction
HUS	NNP	hus	hus	hu	N	B-AdverseReaction
)	)	)	)	)	N	O
including	VBG	including	including	includ	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
outcome	NN	outcome	outcome	outcom	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
TTP	NNP	ttp	ttp	ttp	N	O
HUS	NNP	hus	hus	hu	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
the	DT	the	the	the	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
is	VBZ	is	is	is	N	O
suspected	VBN	suspected	suspected	suspect	N	O
,	,	,	,	,	N	O
stop	VB	stop	stop	stop	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
and	CC	and	and	and	N	O
evaluate	NN	evaluate	evaluate	evalu	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
the	DT	the	the	the	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
of	IN	of	of	of	N	O
TTP	NNP	ttp	ttp	ttp	N	O
HUS	NNP	hus	hus	hu	N	O
is	VBZ	is	is	is	N	O
excluded	VBN	excluded	excluded	exclud	N	O
,	,	,	,	,	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
restarted	VBN	restarted	restarted	restart	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
reinitiating	VBG	reinitiating	reinitiating	reiniti	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
therapy	NN	therapy	therapy	therapi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
previously	RB	previously	previously	previous	N	O
experiencing	VBG	experiencing	experiencing	experienc	N	O
TTP	NNP	ttp	ttp	ttp	N	O
HUS	NNP	hus	hus	hu	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
known	VBN	known	known	known	N	O
.	.	.	.	.	N	O

5.13	CD	5.13	5.13	5.13	N	O
Posterior	NNP	posterior	posterior	posterior	N	O
Reversible	NNP	reversible	reversible	revers	N	O
Encephalopathy	NNP	encephalopathy	encephalopathy	encephalopathi	Y	O
Syndrome	NNP	syndrome	syndrome	syndrom	N	O
(	(	(	(	(	N	O
PRES	NNP	pres	pres	pre	N	O
)	)	)	)	)	N	O

Cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
PRES	NNP	pres	pres	pre	N	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
.	.	.	.	.	N	O

Posterior	NNP	posterior	posterior	posterior	N	O
reversible	JJ	reversible	reversible	revers	N	O
encephalopathy	JJ	encephalopathy	encephalopathy	encephalopathi	Y	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
(	(	(	(	(	N	O
PRES	NNP	pres	pres	pre	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
formerly	RB	formerly	formerly	formerli	N	O
termed	VBD	termed	termed	term	N	O
Reversible	JJ	reversible	reversible	revers	N	O
Posterior	NNP	posterior	posterior	posterior	N	O
Leukoencephalopathy	NNP	leukoencephalopathy	leukoencephalopathy	leukoencephalopathi	Y	O
Syndrome	NNP	syndrome	syndrome	syndrom	N	O
(	(	(	(	(	N	O
RPLS	NNP	rpls	rpls	rpl	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
neurological	JJ	neurological	neurological	neurolog	N	O
disorder	NN	disorder	disorder	disord	N	O
which	WDT	which	which	which	N	O
can	MD	can	can	can	N	O
present	VB	present	present	present	N	O
with	IN	with	with	with	N	O
seizure	NN	seizure	seizure	seizur	Y	O
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	O
,	,	,	,	,	N	O
lethargy	NN	lethargy	lethargy	lethargi	Y	O
,	,	,	,	,	N	O
confusion	NN	confusion	confusion	confus	Y	O
,	,	,	,	,	N	O
blindness	NN	blindness	blindness	blind	Y	O
,	,	,	,	,	N	O
altered	VBD	altered	altered	alter	N	O
consciousness	NN	consciousness	consciousness	conscious	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
visual	JJ	visual	visual	visual	N	O
and	CC	and	and	and	N	O
neurological	JJ	neurological	neurological	neurolog	N	O
disturbances	NNS	disturbances	disturbance	disturb	N	O
,	,	,	,	,	N	O
along	IN	along	along	along	N	O
with	IN	with	with	with	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
is	VBZ	is	is	is	N	O
confirmed	VBN	confirmed	confirmed	confirm	N	O
by	IN	by	by	by	N	O
neuro	JJ	neuro	neuro	neuro	N	O
-	:	-	-	-	N	O
radiological	JJ	radiological	radiological	radiolog	N	O
imaging	NN	imaging	imaging	imag	N	O
(	(	(	(	(	N	O
MRI	NNP	mri	mri	mri	Y	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
if	IN	if	if	if	N	O
PRES	NNP	pres	pres	pre	N	O
is	VBZ	is	is	is	N	O
suspected	VBN	suspected	suspected	suspect	N	O
and	CC	and	and	and	N	O
evaluate	VB	evaluate	evaluate	evalu	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
reinitiating	VBG	reinitiating	reinitiating	reiniti	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
therapy	NN	therapy	therapy	therapi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
previously	RB	previously	previously	previous	N	O
experiencing	VBG	experiencing	experiencing	experienc	N	O
PRES	NNP	pres	pres	pre	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
known	VBN	known	known	known	N	O
.	.	.	.	.	N	O

5.14	CD	5.14	5.14	5.14	N	O
Embryo	NNP	embryo	embryo	embryo	N	O
-	:	-	-	-	N	O
fetal	JJ	fetal	fetal	fetal	N	O
Toxicity	NN	toxicity	toxicity	toxic	N	O

Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
fetal	JJ	fetal	fetal	fetal	N	B-AdverseReaction
harm	NN	harm	harm	harm	N	I-AdverseReaction
when	WRB	when	when	when	N	O
administered	VBN	administered	administered	administ	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
woman	NN	woman	woman	woman	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
its	PRP$	its	it	it	N	O
mechanism	NN	mechanism	mechanism	mechan	N	O
of	IN	of	of	of	N	O
action	NN	action	action	action	N	O
and	CC	and	and	and	N	O
findings	NNS	findings	finding	find	N	O
in	IN	in	in	in	N	O
animals	NNS	animals	animal	anim	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
are	VBP	are	are	are	N	O
no	DT	no	no	no	N	O
adequate	JJ	adequate	adequate	adequ	N	O
and	CC	and	and	and	N	O
well	RB	well	well	well	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
studies	NNS	studies	study	studi	N	O
in	IN	in	in	in	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
women	NNS	women	woman	women	N	O
using	VBG	using	using	use	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
.	.	.	.	.	N	O

Carfilzomib	NNP	carfilzomib	carfilzomib	carfilzomib	N	O
caused	VBD	caused	caused	caus	N	O
embryo	SYM	embryo	embryo	embryo	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
fetal	JJ	fetal	fetal	fetal	N	I-AdverseReaction
toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
in	IN	in	in	in	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
rabbits	NNS	rabbits	rabbit	rabbit	N	B-Animal
at	IN	at	at	at	N	O
doses	NNS	doses	dos	dose	N	O
that	WDT	that	that	that	N	O
were	VBD	were	were	were	N	O
lower	JJR	lower	lower	lower	N	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
the	DT	the	the	the	N	O
recommended	VBN	recommended	recommended	recommend	N	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

Females	NNS	females	female	femal	N	O
of	IN	of	of	of	N	O
reproductive	JJ	reproductive	reproductive	reproduct	N	O
potential	NN	potential	potential	potenti	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
advised	VBN	advised	advised	advis	N	O
to	TO	to	to	to	N	O
avoid	VB	avoid	avoid	avoid	N	O
becoming	VBG	becoming	becoming	becom	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
while	IN	while	while	while	N	O
being	VBG	being	being	be	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
Kyprolis	NNP	kyprolis	kyprolis	kyproli	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
this	DT	this	this	thi	N	O
drug	NN	drug	drug	drug	N	O
is	VBZ	is	is	is	N	O
used	VBN	used	used	use	N	O
during	IN	during	during	dure	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
if	IN	if	if	if	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
becomes	VBZ	becomes	becomes	becom	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
while	IN	while	while	while	N	O
taking	VBG	taking	taking	take	N	O
this	DT	this	this	thi	N	O
drug	NN	drug	drug	drug	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
apprised	VBN	apprised	apprised	appris	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
hazard	NN	hazard	hazard	hazard	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
fetus	NN	fetus	fetus	fetu	N	O
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.1	CD	8.1	8.1	8.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

